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c-Myc is frequently deregulated in human cancers.  While deregulated c-
Myc leads to tumor growth, it also triggers apoptosis in partnership with tumor 
suppressors such as ARF and p53.  Apoptosis induced by c-Myc is a critical fail-
safe mechanism for the cell to protect against unrestrained proliferation.  Despite 
the plethora of information on c-Myc, the molecular mechanism of how c-Myc 
induces both transformation and apoptosis is unclear.  Oncogenic c-Myc can 
indirectly induce the expression of the tumor suppressor ARF, which leads to 
apoptosis through the stabilization of p53, but both c-Myc and ARF have 
apoptotic activities that are independent of p53.  In cells without p53, ARF 
directly binds to c-Myc protein and inhibits c-Myc-induced hyperproliferation and 
transformation with a concomitant inhibition of canonical c-Myc target gene 
induction.  However, ARF is an essential cofactor for p53-independent c-Myc-
induced apoptosis.  Here we show that ARF is necessary for c-Myc to drive 
transcription of a novel noncanonical target gene, Egr1.  In contrast, c-Myc 
induces another family member, Egr2, through a canonical mechanism that is 
inhibited by ARF.  We further demonstrate that Egr1 is essential for p53-
independent c-Myc-induced apoptosis, but not ARF-independent c-Myc-induced 
apoptosis.  Therefore, ARF binding switches the inherent activity of c-Myc from a 
proliferative to apoptotic protein without p53 through a novel noncanonical 
transcriptional mechanism.   These findings also provide evidence that cofactors 
can differentially regulate specific transcriptional programs of c-Myc leading to 
different biological outcomes. 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRANSCRIPTIONAL REGULATION OF MYC BY  
THE TUMOR SUPPRESSOR ARF 
By 
David Nelson Boone 
 
Dissertation 
Submitted to the Faculty of the  
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
In 
Cell and Developmental Biology 
May, 2011 
Nashville, Tennessee  
Approved: 
Professor Stephen R. Hann 
Professor Steven R. Hanks 
Professor Ethan Lee 
Professor Scott Hiebert 
Professor Antonis Hatzopoulos 
 
  ii 
 
 
 
 
 
 
 
To my wonderful daughter, Gabrielle, my little peanut, my angel, infinitely wise, 
beautiful, creative, inquisitive, caring, and joyful. 
 
 
 
 
 
 
 
 
 
 
  iii 
ACKNOWLEDGEMENTS 
 
 I am blessed because I have been surrounded and supported by many 
caring and intelligent people throughout my graduate career and life as a whole.  
Without these people nothing would be possible.  First I would like to thank my 
mentor, Stephen Hann.  Not only did he guide me to become a more competent 
scientist through engaging and thought-provoking discussions, but he also did so 
through allowing and encouraging me to disagree with him and to learn through 
my own mistakes.  Often, I felt not only like a student of his, but also like a 
colleague, and for that I thank him.  Further, his understanding of the transient 
nature of life allowed me to be the type of father that I wanted to be, as well as, to 
pursue my interests in teaching.  His infinite trust in me to be productive while 
teaching a day a week for the past three years is remarkable, and for that trust, 
his friendship, and his guidance I am forever grateful.  I would also like to thank 
the members of my committee, Steve Hanks, Scott Hiebert, Ethan Lee, and 
Antonis Hatzopoulos for the structure, focus, guidance, and insights that they 
provided. I would like to extend a special thanks to the chair of my committee, 
Steve Hanks, for his encouragement and support throughout my graduate 
career, and to Antonis Hatzopoulos for careful review of this dissertation.  
Without my committee, it is possible that I would still be moving in many 
directions at once.  I also thank my previous mentors, Nicholas Hawrylak, 
Adrienne Salm, and Blair S. Hedges for their encouragement and for sparking my 
interest in biomedical research. 
  iv 
 I would like to thank the members of the Hann lab both past and present for 
their support and friendship.  I thank Julian Li, a member of the lab through the 
duration of my graduate career, for always teaching me the intricacies of Myc, as 
well as, the cell and molecular biology techniques needed to study to it.  I thank 
Qin Zhang for her many insights and discussions about all things scientific and 
otherwise.  I thank Hollie Parker for taking care of the lab and for making it an 
enjoyable place.  Without her friendship, bread, loud obnoxious comments, and 
common musical interests the many hours spent at lab certainly would not have 
been as fun.  I also thank Alex Panaccione, and wish him the best of luck on the 
rest of his gradate career.  I would also like to thank Ying Qi for performing the 
microarrays that were the basis for my project, and Mark Gregory and Kim West-
Osterfield for their part in recruiting me to the Hann lab.   
 I thank all of my teachers from elementary school through graduate school 
for giving so freely to me.  It was their selflessness that inspired me to work for 
the Center for Science Outreach (CSO), which was infinitely rewarding.  I would 
like to thank Virginia Shepherd, Jeannie Tuschl, and everyone at the CSO for 
giving me the opportunity to work with them.  Thank you not only for providing an 
environment to grow as an instructor, but also for connecting me to the 
community and making Nashville a home.   Further, I would like to thank Carrie 
Scurlock, June Stevens, Angela Eeds, Chris Vanags, Jonathan Creamer, and 
Mary Loveless—the teachers/instructors I worked with during my time at the 
CSO—for showing me how to teach and for being heroes that are educating and 
shaping the young minds of our community. 
  v 
 Finally, I would like to thank my friends and family for their endless support 
and love.  My friends—the GC crew, the ole college chums, the class of 13ish, 
and all those in-between—have the uncanny ability to make me laugh and cry.  
Thank you for being my ‘village’ to raise my daughter, and for everything else 
that went along with all the times that will go unmentioned.   I thank my 
grandmother, Sarah Boone, for teaching me to count through incessant bouts of 
canasta.  I thank my sister, Tamara, for endless reasons, for her constant love, 
for reading to me as a child, for inspiring me scientifically and otherwise, and for 
her support during my maturation from a child into an individual.  I thank my 
parents, Nelson and Joyce Boone, for simply everything.  It is their care, 
sacrifice, support, love, teachings, etc. that has given me all that I have.  I thank 
them for pushing me to be the best that I can and for giving up so much to make 
sure I have every opportunity to accomplish any goal of my choosing.  I hope 
they understand how much I appreciate and love them.  Finally, I would like to 
thank my girls, Danielle and Gabrielle.  Danielle’s endless love for Gabbie and I 
never ceases to amaze me.  I must apologize to her for the many weekends she 
spent in lab with me, but I am very thankful for all of our time together.  I also 
thank her for her love, laughter, and support and for giving me the greatest little 
girl.  Finally, and most importantly, I would like to thank my daughter Gabrielle for 
being a constant source of inspiration, hope, love, bewilderment, joy, and faith.  I 
thank her so much for teaching me about all that is important in life. She will 
certainly do greater things than any of us can imagine, and I am blessed to be 
her father.      
  vi 
TABLE OF CONTENTS 
 
 
Page 
 
DEDICATION ........................................................................................................ ii 
 
ACKNOWLDEDGEMENTS  ................................................................................. iii 
 
LIST OF TABLES  .............................................................................................. viii 
 
LIST OF FIGURES  .............................................................................................. ix 
 
LIST OF ABBREVIATIONS  .................................................................................xi 
 
Chapter 
 
I.  INTRODUCTION  .................................................................................. 1 
 
  Biological functions and significance of c-Myc  ................................... 1  
  c-Myc as a transcription factor  ........................................................... 2 
  c-Myc and apoptosis  .......................................................................... 8 
   Overview of apoptosis as a fail-safe to inhibit hyperproliferation 8 
   c-Myc and p53  ......................................................................... 10 
   p53-independent apoptosis:  c-Myc and ARF  .......................... 14 
  Egr transcription factors  ................................................................... 16 
 
 II.  EGR1 IS A DIRECT ARF-DEPENDENT C-MYC TARGET GENE  ...... 19 
 
  Introduction  ...................................................................................... 19 
  Materials and Methods  ..................................................................... 20 
   Cell culture  ............................................................................... 20 
   Cell transfection and infection  .................................................. 21 
   Plasmids and expression vectors  ............................................ 22 
   Cell treatments  ......................................................................... 22 
   RNA interference  ..................................................................... 23 
   Antibodies  ................................................................................ 23 
   Western blot analysis  ............................................................... 24 
   Quantitative real-time RT-PCR  ................................................ 25 
   Chromatin immunoprecipitation  ............................................... 26   
   Luciferase assays  .................................................................... 28 
   Real time RT-PCR primers  ...................................................... 29 
   ChIP primers  ............................................................................ 29 
   qChIP primers ............................................................................ 31 
   
 
  vii 
  Results  ............................................................................................. 32 
Differential induction of Egr1 and Egr2 by activated c-Myc 
depending on the presence of ARF  ......................................... 32 
ARF is necessary for c-Myc to induce Egr1 .............................. 34  
Egr1 is a direct target gene of c-Myc  ....................................... 37 
Egr1 protein induction by c-Myc  .............................................. 40 
Endogenous c-Myc regulates Egr1 levels  ............................... 43 
c-Myc and ARF are recruited to the Egr1 promoter  ................. 45 
   c-Myc and ARF regulate the Egr1 promoter  ............................ 50 
   Loss of N-terminal ubiquitination mimics ARF control of c-Myc- 
   induced Egr1 expression  ......................................................... 54 
  Discussion  ........................................................................................ 55 
 
 III.  EGR1 IS NECESSARY FOR C-MYC INDUCED P53-INDEPENDENT  
       APOPTOSIS  ....................................................................................... 61 
   
  Introduction  ...................................................................................... 61 
  Materials and Methods  ..................................................................... 62 
   Cell culture  ............................................................................... 62 
   Retroviral infection  ................................................................... 62 
   Plasmids and expression vectors  ............................................ 63 
   Cell treatments  ......................................................................... 63 
   RNA interference  ..................................................................... 64 
   Antibodies  ................................................................................ 64 
   Western blot analysis  ............................................................... 65 
   Apoptosis assays  ..................................................................... 65 
  Results  ............................................................................................. 66 
   Egr1-/- MEFs are deficient in c-Myc-induced apoptosis  .......... 66 
   Reduced Egr1 and/or ARF expression inhibits c-Myc induced    
   p53-independent apoptosis  ..................................................... 67 
   Egr1 is necessary specifically for c-Myc-induced p53- 
   independent apoptosis  ............................................................. 70 
   Egr1 is sufficient for p53-independent apoptosis ...................... 73 
   Egr1 is necessary for apoptosis induced by c-MycN6KR-ER  .. 76 
  Discussion  ........................................................................................ 79 
 
 IV.  CONCLUSIONS  ................................................................................. 85 
 
  The Myc/ARF/Egr1 pathway as a fail-safe mechanism  .................... 85 
  ARF:  an unusual cofactor  ................................................................ 87 
  Transcriptional regulation by ARF:  a p53-independent function  ..... 88 
  The cofactor switch model  ............................................................... 90 
  Future directions  ............................................................................... 93 
 
 REFERENCES  ......................................................................................... 96 
 
  viii 
LIST OF TABLES 
 
 
 
Table            Page 
 
2-1 Egr factors are potential ARF-dependent targets of c-Myc.  ..................... 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ix 
LIST OF FIGURES 
 
 
 
Figure Page 
 
1-1. Domains of c-Myc and their binding proteins  ........................................... 5 
 
1-2.   c-Myc-induced apoptosis  ....................................................................... 11 
 
2-1.  c-Myc differentially induces Egr1 and Egr2 depending on the  
presence of ARF  .................................................................................... 35 
 
2-2.   c-Myc induces Egr1 mRNA levels in Rat1 cells  ........................................... 36 
 
2-3.   ARF is necessary for the c-Myc induction of Egr1  ................................. 38 
 
2-4.  c-Myc induces Egr1 mRNA in the absence of protein synthesis  ................. 39 
 
2-5.   c-Myc does not influence the stability of Egr1 mRNA  .................................. 41 
 
2-6.   Activation of c-Myc induces Egr1 protein levels only in the  
presence of ARF  .................................................................................... 42 
 
2-7.   Endogenous c-Myc is necessary for the full expression and  
induction of Egr1  ...........................................................................................44 
 
2-8.    c-Myc is recruited to the Egr1 promoter at a noncanonical binding  
site  ................................................................................................................. 46 
 
2-9.   ARF is recruited with c-Myc to the Egr1 promoter  ....................................... 48 
 
2-10.  c-Myc is recruited to the Egr2 promoter at a canonical binding site  ............ 51 
 
2-11.  c-Myc activates the Egr1 promoter in the presence of ARF  ................... 52 
 
2-12.  Diagrammatic representation showing c-Myc protein structure  
and lysines mutated in MycN6KR  .......................................................... 56 
 
2-13.  MycN6KR induces Egr1 but not canonical c-Myc target genes  
in cells without ARF  ................................................................................ 57 
 
3-1.   Activated c-Myc cannot induce cell death in Egr1-/- MEFs  .................... 68 
 
3-2.   siRNA treatment suppresses Egr1 protein for 5 days and following  
MycER activation  ................................................................................... 69 
  x 
 
3-3.    Egr1 and ARF are necessary for c-Myc induced p53-independent  
cell death  ....................................................................................................... 71 
 
3-4.   Egr1 is necessary for c-Myc induced p53-independent apoptosis  ......... 72 
 
3-5.   Treatment with single siRNA oligos targeting Egr1 is sufficient to  
reduce c-Myc-induced p53-independent apoptosis  ............................... 74 
 
3-6.   Egr1 is necessary for c-Myc-induced p53-independent apoptosis,  
but not p53-dependent apoptosis  ........................................................... 75 
 
3-7.   Inhibition of Egr1 expression does not inhibit staurosporine-induced 
apoptosis  ....................................................................................................... 77 
 
3-8.   Activation of Egr1ER induces apoptosis in p53-/- MEFs  ..............................78 
 
3-9.  c-MycN6KR induces apoptosis in p53/ARF double knockout MEFs  ...... 80 
 
3-10.   Model of c-Myc-ARF-Egr1 pathway  ..............................................................82 
 
4-1.   Cofactor Switch Model  ........................................................................... 92 
 
 
 
 
 
 
 
 
 
 
  xi 
LIST OF ABBREVIATIONS 
 
ARF   Alternative Reading Frame protein 
AR   acidic region  
ATM      ataxia telangiectasia mutated protein 
Asp   Aspartic acid 
Ac-DEVD-pNA acetyl-Asp-Glu-Val-Asp p-nitroanilide 
ATR   ataxia telangiectasia and Rad3 related 
b-HLH-LZ  basic-helix-loop-helix-leucine zipper 
Bax   BCL2-associated X protein   
Bcl2   B-cell lymphoma 2 protein  
BH3   Bcl-2 homology domain 3 
Bid   BH3 interacting domain 
Bak   BCL2-antagonist/killer 1 
BSA   bovine serum albumin 
c1,c2,c3  clone1, 2, 3 
C-terminus carboxy-terminus 
CDK4  cyclin-dependent kinase 4 
  xii 
CDKi  cyclin-dependent kinase inhibitor 
CDKN2A  cyclin-dependent kinase inhibitor 2a 
ChIP   chromatin immunoprecipitation 
CMV   cytomegalovirus (promoter) 
CS   calf serum 
CTD   carboxy-terminal domain 
DKO   double knock out 
DMEM  Dulbecco’s modified Eagle medium 
DMSO  dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
Dnmt3a  DNA (cytosine-5)-methyltransferase 3A 
DOC   deoxycholic acid 
ECL   enhanced chemiluminescence  
EDTA  ethylenediaminetetraacetic acid 
Egr   early growth response 
Egr1-ER  Egr1 estrogen receptor 
eIF4E  eukaryotic translation initiation factor 4E 
Elf1a  eukaryotic translation initiation factor 1a 
  xiii 
EMS   E-box Myc sequence 
ER   estrogen receptor 
ETOH  ethanol 
FBS   fetal bovine serum 
Fbw7  F-box and WD repeat domain-containing 7 
fwd   forward 
G1   gap1 phase 
G2   gap2 phase 
Gadd  growth arrest and DNA damage 
Glu   Glutamic acid 
GnRH  gonadotropin-releasing hormone 
HA   hemagglutinin 
HAT   histone acetyltransferase 
HDAC  histone deacetylase 
Hygro  hygromycin 
IB   immunoblot 
IgG   Immunoglobulin G 
IL-3   interleukin 3 
  xiv 
Inr   initiator element 
IP   immunoprecipitation 
Kbs   kilobases 
KOAc  potassium acetate 
Luc   luciferase 
M   molarity 
MBI/II/III  Myc boxI/II/III 
MCS   multicloning site  
MEFs  mouse embryonic fibroblasts 
MgOAc  magnesium acetate 
min   minute 
Miz1   Myc-interacting zinc finger 1 
mRNA  messanger RNA 
MT-MC1  Myc Target in Myeloid Cells 1 
mxi   max interacting protein  
MycER  Myc estrogen receptor 
Mycfl  Myc full length 
MycN6KR-ER 6 lysine-to-arginine mutant in the N-terminus of MycER 
  xv 
N-terminus amino-terminus  
NLS   nuclear localization signal   
NP40  nonyl phenoxypolyethoxylethano 
NPM   nucleophosmin 
NTD   amino-terminal domain 
ODC   ornithine decarboxylase 
OHT   4-hydroxytamoxifin  
PCR   polymerase chain reaction 
PDGF-β  platelet derived growth factor β receptor  
PMSF  phenylmethanesulfonylfluoride 
pRL-SV40 renilla luciferase Simian virus 40 
pRL-TK  renilla luciferase thymidine kinase 
P-TEF-b  Positive Transcription Elongation Factor b 
PTEN  phosphatase and tensin homolog    
Puro   puromycin 
rev   reverse 
RNAi  RNA interference 
RNA   ribonucleic acid 
  xvi 
RT-PCR  reverse-transcriptase polymerase chain reaction 
S phase  synthesis phase 
s.d.   standard deviation 
SDS   sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siCtl   small interfering control 
siRNA  small interfering RNA 
Skp2  S-phase kinase-associated protein 2 
Sp1/Sp3  specificity protein 1/3 
Staph A  Staphylococcus aureus 
Taq   Thermus aquaticus  
Tbp   TATA-binding protein 
TBS   tris-buffered saline 
tert   telomerase reverse transcriptase  
TFII-I  transcription factor II-I 
TGFβ1  transforming growth factor beta 
TRD   transcriptional regulatory domain 
TRRAP  transformation/transcription domain-associated protein 
  xvii 
WB   Western blot 
WT   wild-type   
Val   valine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1	  
CHAPTER I 
 
INTRODUCTION 
         
Biological Functions and Significance of c-Myc 
The complexities of c-Myc have plagued investigators for well over the 
past quarter of a century.  However, with the deregulation of c-Myc being one of 
the most prevalent alterations in many types of human cancer—Burkitt’s 
lymphoma, myeloid and plasma cell leukemias; breast, cervical, small cell lung, 
and colon carcinomas; osteosarcoma; and glioblastoma (Spencer and Groudine 
1991; Nesbit et al. 1999; Adhikary and Eilers 2005)—and because c-Myc has 
been implicated in many of the diverse biological functions leading to 
tumorigenesis (Pelengaris et al. 2002), it is not surprising that extensive time and 
effort continue to be dedicated to understanding how this small molecule 
functions.  Through the years, researchers have discovered many diverse and 
sometimes contradictory, but nonetheless crucial, biological functions of c-Myc.  
The vital importance of c-Myc is accentuated by the embryonic lethality of c-myc 
knockout mice (Davis et al. 1993).  Overexpression of c-Myc increases 
progression through the cell cycle by shortening G1 and G2, drives cell cycle 
entry in the absence of growth factors, contributes to genomic instability and 
chromosomal alterations, increases cell growth, prevents terminal differentiation, 
and causes hyperproliferation, immortalization, and transformation in cell culture 
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and tumorigenesis in transgenic animals (Henriksson and Luscher 1996; 
Lemaitre et al. 1996; Facchini and Penn 1998; Felsher and Bishop 1999; Li and 
Dang 1999).  In contrast, c-Myc overexpression also leads to apoptosis in cells 
deprived of growth factors (Askew et al. 1991; Evan et al. 1992; Bissonnette et 
al. 1994; Evan and Littlewood 1998).  Additionally, the ability of endogenous c-
Myc to drive these two conflicting processes—proliferation and apoptosis—is 
emphasized in c-myc-/- cells, which have both a slow growth phenotype due to 
lengthened G1 and G2 cell cycle phases and an apoptotic defect due to an 
unknown mechanism (Mateyak et al. 1997).   
The complex and contradictory roles of c-Myc provoke many questions.  
How does a single protein contribute to numerous crucial and diverse biological 
functions?  Is there a molecular mechanism to switch c-Myc from driving 
proliferation to initiating apoptosis?  Can interaction with specific cofactors lead to 
differential regulation?  Are there direct target genes of c-Myc that are specific to 
induce apoptosis?  How do cancerous cells utilize c-Myc functions to survive and 
proliferate while bypassing its apoptotic effects?  Unfortunately the answers to 
these important questions remain elusive.  The goal of this thesis is to investigate 
the molecular mechanisms involved in c-Myc function, specifically focusing on 
the transcriptional and apoptotic regulation by the tumor suppressor ARF.  
 
c-Myc as a transcription factor 
The c-Myc protein is a transcription factor of the basic helix-loop-helix-
leucine zipper (b-HLH-LZ) family that activates and represses gene expression 
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(Landschulz et al. 1988; Murre et al. 1989; Kato et al. 1990; Adhikary and Eilers 
2005).  c-Myc has a typical transcription factor modular structure with a b-HLH-
LZ dimerization/DNA binding domain at the C-terminus and a transcriptional 
regulatory domain (TRD) at the N-terminus (Figure 1-1) (Kato et al. 1990).  
Dimerization with Max, a ubiquitously expressed b-HLH-LZ partner protein, and 
direct binding to specific DNA sequences is required for c-Myc function 
(Blackwood and Eisenman 1991).  The E-box, CACGTG, is the ‘canonical’ 
sequence bound by Myc/Max, but many other high affinity ‘non-canonical’ 
sequences exist that Myc/Max associate with both in vitro and in vivo (Blackwell 
et al. 1990; Blackwell et al. 1993).  Although the significance of target genes that 
contain these non-canonical sequences is unknown, their importance is 
unmistakable given the data from global binding studies that demonstrate only a 
minority of sites bound in vivo have the consensus sequence (Fernandez et al. 
2003; Li et al. 2003; Adhikary and Eilers 2005).  
The recruitment of multiple co-activators to E-box elements by interaction 
with the N-terminal domain of c-Myc is essential for target gene activation (Figure 
1-1) (Cowling and Cole 2006).  One such cofactor, TRRAP, is an adaptor protein 
that binds c-Myc at a conserved region in the N-terminus called Myc Box II (MBII) 
(McMahon et al. 1998).  Chromatin structure of c-Myc regulated promoters is 
subsequently altered—acetylated—by the histone acetyltransferases (HATs), 
GCN5 and TIP60, bound to TRRAP (Ikura et al. 2000; Strahl and Allis 2000; 
Brown et al. 2001; Liu et al. 2003).  Acetylated chromatin is an ‘open’ 
conformation that is accessible to general transcription factors, and this alteration 
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of chromatin status is a critical way that c-Myc mediates gene expression.  The 
ATPases/helicases TIP48 and TIP49 also bind MBII and alter chromatin 
structure, but through a TRRAP-independent mechanism (Wood et al. 2000).  
Another cofactor recruited by c-Myc that affects up-regulation of target genes in a 
different manner is the kinase P-TEFb, which facilitates transcriptional elongation 
by enhancing the phosphorylation of the C-terminal domain of RNA polymerase II 
(Eberhardy and Farnham 2002).  Furthermore, many other cofactors have been 
identified that are recruited to E-boxes by c-Myc that are important for different 
mechanisms of gene regulation (Cowling and Cole 2006).  However, despite the 
understanding of how numerous different cofactors affect c-Myc mediated 
activation, it is unknown if specific cofactors can influence which of the many c-
Myc target genes are regulated.  Nevertheless, the discovery that TRRAP 
binding increases up-regulation of cyclinD2 and tert but not cad suggests that 
cofactor binding can differentially regulate the induction of c-Myc target genes 
(Eberhardy et al. 2000; Eberhardy and Farnham 2001).  
The regulation of gene expression by c-Myc is complicated by and often 
dependent on other transcription factors.  Many other transcription factors bind 
and regulate the same genes and also the same sites as the Myc/Max hetero-
dimer (Blackwell et al. 1990; Blackwell et al. 1993).  In fact, Max can form 
heterodimers with several other related b-HLH proteins known as Mad, Mxi, and 
Mnt that bind E-box sequences and repress transcription by recruiting histone 
deacetylases (HDACs) through the adaptor protein SIN3 (Ayer et al. 1993; 
Zervos et al. 1993; Hurlin et al. 1997).    Another way c-Myc is thought to activate  
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Figure 1-1.  Domains of c-Myc and their binding proteins.  c-Myc has a 
typical transcription factor structure with a C-terminal domain (CTD) consisting of 
a basic (B) helix-loop-helix (HLH) leucine zipper (LZ) necessary for DNA binding.  
It also contains the nuclear localization signal (NLS).  The N-terminal domain 
(NTD) is the transcriptional regulatory domain (TRD) that recruits cofactors to 
DNA to influence transcription.  Conserved regions between family members and 
species are denoted as Myc boxes (MBI, MBII, MBIII).  The function of the acidic 
region (AR) in the central part of the protein is unknown.  The numbers under the 
diagram represent amino acid position.  The black bars under the diagram 
indicate the region of interaction by the protein listed on the right.   Dimerization 
with MAX is necessary for all of c-Myc’s functions.  When c-Myc interacts with 
Miz1 it represses transcription by preventing the transcriptional activities of Miz1.  
TRRAP recruits the histone acetyltransferases (HATs) GCN5 and TIP60 to the 
promoter.  TIP48 and TIP49 are involved in chromatin remodeling.  P-TEFb is a 
kinase that phosphorylates the c-Terminal tail of RNA polymerase II to initiate 
transcriptional elongation.  Fbw7 is not a cofactor of c-Myc, but is an E3 ubiquitin 
ligase that regulates c-Myc protein stability.  Skp2 is also part of an E3 ubiquitin 
ligase complex, but it also functions as a cofactor for c-Myc increasing the 
transcriptional induction of several canonical targets.  The interaction with ARF 
switches c-Myc from driving canonical target gene up-regulation, 
hyperproliferation, and transformation to shutting down canonical transactivation 
while inducing apoptosis.  
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transcription is simply by de-repression, whereby Myc/Max compete with these 
repressive complexes that bind to E-boxes. Additionally, c-Myc can mediate 
repression of target genes, but this does not happen at E-boxes or any other 
simple consensus sequence and may not even require direct DNA binding 
(Kleine-Kohlbrecher et al. 2006).  Instead repression by c-Myc occurs by poorly 
defined mechanisms that involve c-Myc binding to general transcription factors 
like TFII-I or other transcription factors such as Miz1, Sp1, and Sp3 at Inr 
elements or other regions of core promoters in target genes (Li et al. 1994; Yang 
et al. 2001).  How c-Myc represses rather than activates these genes is 
unknown, but it may involve recruitment of distinct cofactors to target sites of 
repression.  For example, instead of recruiting HATs to Miz1 bound targets of 
repression it was shown that c-Myc is necessary for the recruitment of the DNA 
methyl-transferase Dnmt3a (Brenner et al. 2005).  Furthermore, though it is 
believed that the control of eukaryotic transcription is to a large extent 
combinatorial, the effects of other transcription factors binding simultaneously 
with c-Myc at target gene promoters have not been examined.  However, a 
bioinformatics approach did identify a few factors, including Egr1, whose binding 
sites are overrepresented in c-Myc target gene promoters (Elkon et al. 2004). 
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c-Myc and Apoptosis 
 
Overview of apoptosis as a fail-safe to inhibit hyperproliferation 
In response to mitogens, the expression of c-Myc and other factors such 
as E2F are induced.  They then promote cell cycle progression by up-regulation 
of specific genes.  E2F has a logical set of target genes that elicit the onset of S 
phase, including cyclins, enzymes involved in maintaining nucleotide pools, and 
DNA polymerase itself (Patel et al. 2004).  Unfortunately, the important target 
genes necessary for c-Myc to induce cell cycle progression have been far more 
difficult to elucidate due to the fact that most of the defined target genes of c-Myc 
are important in other biological functions, like ribosome biogenesis and 
metabolism.  It is currently believed that the induction of cyclinD2 and CDK4 are 
important for c-Myc to drive the cell cycle (Patel et al. 2004; Adhikary and Eilers 
2005).  However, neither of these genes, nor any other defined target gene, can 
completely rescue the slow growth phenotype of Myc null cells, although 
ornithine decarboxylase (ODC) or MT-MC1 overexpression can partially enhance 
proliferation in these cells (Berns et al. 2000; Yin et al. 2002; Cohen and 
Prochownik 2006).  Because none of c-Myc’s direct targets are sufficient to 
induce cell cycle progression and proliferation, and because c-Myc regulates 
many genes involved in many functions, some have suggested that specific 
targets may not lead to proliferation, but rather c-Myc-induced proliferation is 
produced by a combined effect from a large subset of targets involved not only in 
the cell cycle, but also in cell growth. 
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A major pathway in controlling the inhibition of proliferation and the 
induction of apoptosis is the ARF-Mdm2-p53 pathway.  ARF is an unusual tumor 
suppressor that is encoded by an alternative reading frame from the 
evolutionarily conserved Ink4a locus, which also encodes the tumor suppressor 
p16 (Quelle et al. 1995).  It is a highly basic protein that is typically not expressed 
in normal tissues, but rather is induced primarily by prolonged and sustained 
proliferative signals produced by active oncogenes such as c-Myc and Ras 
(Lowe and Sherr 2003).  Because of this it is not surprising that the loss of ARF 
through deletion or epigenetic silencing is a common feature of many human 
cancers (Vonlanthen et al. 1998; Esteller et al. 2000; Sherr 2001).  The prevailing 
view is that the major tumor suppressor functions of ARF are mediated through 
p53 (Sherr 2006).  c-Myc overexpression/deregulation or other hyperproliferative 
stimuli, such as Ras, E1A, or E2F, induce ARF expression, which directly binds 
and inhibits Mdm2, the E3 ubiquitin ligase of p53, resulting in the stabilization of 
p53 (Sherr 1998).  Growth arrest or apoptosis ensue due to p53 target gene up-
regulation of the cyclin dependant kinase inhibitor p21, or pro-apoptotic genes 
such as Bax and PUMA (Yu et al. 2003).  However, accumulating evidence 
suggests that ARF can act as a tumor suppressor, inducing apoptosis and/or 
inhibiting proliferation, independently of p53 by controversial and mostly unknown 
mechanisms.  Additionally, c-Myc also causes apoptosis independently of p53, 
though the mechanism is unknown.  However, the regulation of the Bcl-2 family 
members, Bim, Bax, and Bcl2, by c-Myc has proven important in this process, 
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but all appear to be indirectly regulated by c-Myc (Eischen et al. 2001; Eischen et 
al. 2001; Egle et al. 2004; Hemann et al. 2005).  
 
c-Myc and p53 
 It was surprising when c-Myc, which provides cells with survival and 
proliferative advantages, was shown to also induce apoptosis.  Originally, it was 
observed that a myeloid cell line, 32D, constitutively expressing c-Myc, in 
response to interleukin 3 (IL-3) withdrawal, did not arrest in G1, but did rapidly 
initiate apoptosis (Askew et al. 1991).  Soon after, others demonstrated that Rat-
1 fibroblasts constitutively expressing c-Myc also did not arrest in low serum, 
unlike untransfected Rat-1 cells.  Although the c-Myc expressing Rat-1 cells 
continued to proliferate, their numbers in culture did not increase because 
constitutive c-Myc expression was simultaneously inducing proliferation and 
apoptosis in the absence of mitogenic stimulation creating a nearly steady state 
number of cells (Evan et al. 1992).  We now know that this phenomenon is not 
specific to these cell types or under these conditions, but instead extends to 
many cell types under many different conditions.  In fact, many oncogenes have 
similar built-in fail-safe mechanisms to restrict uncontrolled proliferation—caused 
by their own aberrant signaling—through induction of apoptosis (Harrington et al. 
1994). 
 Not long after the discovery of the role of c-Myc in apoptosis it was shown 
that activation of c-Myc stabilized p53 and induced apoptosis and cell cycle re-
entry in quiescent MEFs  expressing  wild-type  p53  (Hermeking and Eick 1994).  
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Figure 1-2.  c-Myc-induced apoptosis.  Oncogenic c-Myc is involved in a 
complicated web that controls the levels of p53.  c-Myc stabilizes p53 by inducing 
ARF, repressing Mdm2, and indirectly by inducing DNA damage.  In a feedback 
mechanism, p53 reduces its own expression by inducing Mdm2, repressing ARF, 
and reducing c-Myc through the induction of miR-145.  c-Myc and p53 inhibit 
growth and/or induce apoptosis through the regulation of common target genes.  
While p53 directly (solid lines) induces or represses growth inhibitory, pro-
apoptotic, and anti-apoptotic targets, c-Myc appears to do so indirectly (dashed 
lines).  The blue lines represent the direct regulation of ARF on c-Myc that results 
in a differential induction of c-Myc targets and p53-independent apoptosis.  
Exactly what targets are involved is still unknown, but the Myc/ARF interaction 
may explain how c-Myc indirectly regulates the pro- and anti-apoptotic factors    
—some of which may be the same as listed in the p53-dependent pathway— 
independently of p53.  
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This was the birth of the connection between two of the most frequently altered 
proteins in human cancers (Lane 1992).  The most well-established mechanism 
of c-Myc mediated stabilization of p53 is through the ARF/MDM2 pathway 
(Figure 1-2).  c-Myc overexpression/deregulation, induces ARF expression 
through an unknown mechanism.  ARF then directly binds, and inhibits Mdm2, 
the E3 ubiquitin ligase of p53, resulting in stabilization of p53 (Sherr 1998; Sherr 
2001).  There is also evidence that c-Myc binds to and represses the promoter of 
Mdm2, thereby c-Myc may both directly and indirectly decrease the available 
levels of Mdm2 leading to p53 activation (Macias et al. 2009).  Additionally, 
through feedback mechanisms, p53 induces Mdm2 expression (Wu et al. 1993), 
represses ARF expression (Weber et al. 2000), and inhibits c-Myc expression 
through the direct induction of the tumor suppressive miR-145 (Sachdeva et al. 
2009).  Furthermore, overexpressed c-Myc, a common event in human cancer, 
causes DNA damage and genomic instability, which elicits a DNA damage 
response through the ataxia-telangiectasia-mutated (ATM) kinase that ultimately 
results in phosphorylation-dependent stabilization of p53 (Pusapati et al. 2006).  
Thus, c-Myc is involved in a complex and highly regulated web controlling the 
expression of p53 (Figure 1-2).  
 p53, like c-Myc, is a transcription factor that elicits its biological functions 
through transcriptional regulation of target genes (Zambetti et al. 1992; Zambetti 
and Levine 1993; White 1996).  Therefore, stabilized p53 levels leads to either 
growth arrest or apoptosis through target gene regulation.  It is proposed that 
oncogenic c-Myc tips the cell-fate balance toward apoptosis through regulation of 
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overlapping target genes (Nilsson and Cleveland 2003).  p53 activates the 
expression of  the cyclin dependent kinase inhibitor (CDKi) p21 and the growth 
arrest and DNA damage gene gadd45, leading to cell cycle arrest (Benchimol 
2001).  In contrast, c-Myc represses p21 and gadd45, leading to either 
progression through the cell cycle or apoptosis when p53 is also at high levels 
(Herold et al. 2002; Seoane et al. 2002; Wu et al. 2003)(Figure 1-2).  However, 
both c-Myc and p53 can induce levels of pro-apoptotic Bcl-2 and BH3-only family 
members either independently or in concert, although the induction of these 
targets by c-Myc is controversial and appears to be indirect (Benchimol 2001; 
Nilsson and Cleveland 2003; Meyer et al. 2006).  For example, under certain 
conditions both were shown to induce the expression of Bax and Bak, which are 
required for activation of apoptosis through permeabilization of the outer 
membrane of the mitochondria (Galluzzi et al. 2008) leading to cytochrome c 
release. Furthermore, both c-Myc and p53 transcriptionally repress the pro-
survival, anti-apoptotic, Bcl-2 gene (Eischen et al. 2001).  Therefore, c-Myc 
inhibits p53 mediated growth arrest through repression of p21 and gadd genes, 
while simultaneously c-Myc and p53 cooperate to induce apoptosis at the 
mitochondria.  
 
p53-independent apoptosis:  c-Myc and ARF 
 It is evident that ARF is an essential mediator between c-Myc and p53 
because c-Myc induces ARF levels, which ultimately leads to p53 stabilization 
and apoptosis or cell cycle arrest.  However, not only does ARF directly regulate 
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p53 levels and function, but it also directly regulates c-Myc function.  We 
previously found that ARF directly interacts with c-Myc and inhibits c-Myc-
induced hyperproliferation and transformation, while enhancing c-Myc-induced 
apoptosis, even in cells lacking p53.  In fact, c-Myc fails to induce apoptosis 
efficiently in cells lacking both ARF and p53 (Qi et al. 2004), supporting the idea 
that ARF is necessary for efficient p53-independent c-Myc-induced apoptosis in 
fibroblasts.  When c-Myc is activated, nucleolar ARF translocates to the 
nucleoplasm and colocalizes with c-Myc (Qi et al. 2004; Gregory et al. 2005).  In 
the nucleoplasm, we showed that c-Myc and ARF directly interact through co-IPs 
and bind to the same region of several c-Myc target gene promoters through 
ChIP assays.  When ARF is highly expressed and bound to c-Myc target gene 
promoters with c-Myc, ARF inhibits c-Myc’s ability to drive expression of well-
established canonical target genes observed both in real-time RT-PCR assays 
following activation of the inducible c-MycER and in luciferase assays (Qi et al. 
2004).  However, ARF has no effect on genes commonly repressed by c-Myc.  
We believe that the change in target gene regulation caused by ARF led to the 
inability of c-Myc to cause hyperproliferation and transformation, while enhancing 
the ability of c-Myc to induce apoptosis.  Deciphering the molecular mechanism 
of c-Myc-induced, ARF-dependent, p53-independent apoptosis was the goal of 
the studies performed for this thesis.  
In order to understand how the Myc/ARF interaction induced apoptosis 
independently of p53, and hypothesizing that it was through a transcriptional 
mechanism, we performed microarrays by activating c-Myc in p53-/- and in 
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p53/ARF double knock out (DKO) MEFs to determine if ARF inhibited the up-
regulation of all genes by c-Myc.  To our surprise this was not the case.  In fact, 
our results showed that the up-regulation of certain genes like Egr1 and Egr4 are 
actually enhanced by ARF.  Therefore, it appears that the ARF interaction does 
not completely inhibit c-Myc transcription, but rather differentially regulates the 
target genes induced by c-Myc.  In the proceeding chapters, we address if two 
members of the Egr family of transcription factors, Egr1 and Egr2, are direct 
targets of c-Myc and if their differential regulation leads to different biological 
outcomes, with emphasis on whether or not Egr1 is pro-apoptotic. 
 
Egr Transcription Factors 
The Early Growth Response factors are immediate early genes like c-myc, 
c-fos, and c-jun that are rapidly induced in quiescent cells upon mitogenic 
stimulation even in the absence of protein synthesis (Chavrier et al. 1988; Christy 
and Nathans 1989).  The family is a group of four zinc finger transcription factors 
that have highly related zinc finger DNA binding domains, but divergent 
transcription regulatory domains (Beckmann and Wilce 1997; Liu et al. 1998).  
Knockout mice have been made for all family members, and they all have distinct 
phenotypes, suggesting different functions (O'Donovan KJ 1999).  However, 
there is evidence for some level of compensation between family members.  For 
example, luteinizing hormone levels are lower in Egr1/Egr4 double knockout 
mice than in Egr1 knockout mice (Tourtellotte et al. 2000).  Further, Egr1 and 
Egr4, but not Egr2 and Egr3, respond to gonadotropin-releasing hormone 
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(GnRH) (Dorn et al. 1999).  Interestingly, our microarray revealed that c-Myc 
regulates the Egr factors in this same pattern: Egr1/4 are upregulated by c-Myc 
in p53-/- MEFs with high ARF, while Egr2/3 are upregulated in p53/ARF DKO 
MEFs.  
The biological functions of the Egr factors are not entirely known or 
understood, although numerous studies implicate a critical role for them in 
proliferation, apoptosis, inflammation, and differentiation.  A role in proliferation 
for all the Egr factors is suggested because they are induced by mitogens.  
Additionally, it was shown that Egr2 might represent a point of convergence in 
the integration of different signaling pathways leading to the B cell proliferative 
response (Newton et al. 1996).  Pre-T cells have reduced proliferation in 
response to pre-T cell receptor signaling in Egr3 null mice, suggesting Egr3 
promotes proliferation in these cells (Xi and Kersh 2004).  Egr1, the most studied 
family member and the only one extensively examined in MEFs, in contrast to 
Egr2 and Egr3, has a definitive role as a tumor suppressor by inducing apoptosis 
by both p53-dependent and p53-independent mechanisms (Liu et al. 1998).  
Studies show that the expression of Egr1 is undetectable in 72% of human 
breast and non-small cell lung carcinomas and is deleted in 50% of acute 
myeloid leukemias (Liu et al. 1998).  Furthermore, egr1-/- mice are prone to skin 
cancer when challenged with the two-step carcinogenesis model (Krones-Herzig 
et al. 2003).  Additionally, Egr1 is expressed at high levels in terminally 
differentiated cells, and actually Egr1 overexpression abrogates the block 
imparted by c-Myc on terminal M1 myeloid differentiation (Shafarenko et al. 
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2005).  Overexpression of Egr1 in NIH3T3 cells reversibly transformed by 
conditional expression of PDGF-B/v-sis leads to inhibition of proliferation, focus 
formation, and soft agar growth (Mercola et al. 1992).  While reducing Egr1 
expression through dominant-negative or RNAi approaches, inhibits radiation-
induced apoptosis (Muthukkumar et al. 1995; Ahmed et al. 1996).  Further, p53 is 
a direct target of Egr1 as shown by ChIP and real time RT-PCR analyses 
(Krones-Herzig et al. 2005; Yu et al. 2007).  However, even in prostate cancer 
cells that lack p53, Egr1 induction leads to apoptosis (Liu et al. 1998).  Other 
known target genes of Egr1 are the tumor suppressors TGFΒ1 and PTEN, as 
well as, the growth arrest and apoptotic genes gadd45, Bax, Bim, and Fas 
(Baron et al. 2006).  In fact, the site of c-Myc regulation of the gadd45 promoter 
mapped to an Egr binding site (Amundson et al. 1998).  Based on these facts 
and our preliminary data we hypothesized that the Egr transcription factors are 
direct target genes of c-Myc and that Egr1 is induced in an ARF-dependent non-
canonical fashion leading to apoptosis and growth arrest through the induction of 
pro-apoptotic genes.  	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CHAPTER II 
 
EGR1 IS A DIRECT ARF-DEPENDENT C-MYC TARGET GENE 
 
Introduction 
Deregulation or overexpression of the transcription factor c-Myc causes 
hyperproliferation and tumorigenesis and is a driving factor in the majority of 
human cancers (van Riggelen et al. 2010).   Although c-Myc regulates hundreds 
of downstream target genes involved in many different cellular processes, it is 
unclear which target genes mediate specific c-Myc functions (Cohen and 
Prochownik 2006).  Apoptosis in response to deregulated c-Myc is a major fail-
safe mechanism that is essential to prevent the proliferation of tumorigenic cells 
(Sherr 2001).  Apoptosis induced by oncogenic c-Myc occurs through both p53-
dependent and independent mechanisms that are not well understood (Eischen 
et al. 2001; Hemann et al. 2005).  A prevailing model for a p53-dependent 
mechanism is that the tumor suppressor ARF, which is induced by oncogenic c-
Myc, causes the stabilization of the p53 protein by inhibiting its E3 ubiquitin 
ligase Mdm2 (Pomerantz et al. 1998; Zindy et al. 1998).  Additionally, ARF, 
independently of p53, binds to c-Myc directly and blocks the ability of c-Myc to 
activate transcription of examined canonical target genes containing a CACGTG 
E-box Myc binding site (EMS) and also inhibits c-Myc-induced hyperproliferation 
and transformation (Datta et al. 2004; Qi et al. 2004).  Despite this inhibition of 
canonical c-Myc activity, ARF has been shown to be essential for c-Myc to 
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induce p53-independent apoptosis in mouse embryo fibroblasts (MEFs) (Qi et al. 
2004; Gregory et al. 2005).  However, the mechanism of how ARF regulates c-
Myc induced p53-independent apoptosis is unknown.  In this chapter, we 
examined the transcriptional consequences of the c-Myc/ARF interaction and 
discovered that ARF differentially regulates the c-Myc induction of the Egr family 
of transcription factors.  In contrast to ARF blocking the up-regulation of Egr2 and 
other c-Myc canonical target genes, it is necessary for the direct transcriptional 
induction of Egr1 through a novel noncanonical mechanism.   
 
Materials and Methods 
 
Cell culture 
 The p53/ARF double knockout (DKO) mouse embryonic fibroblasts (MEFs) 
were obtained from G. Zambetti (St.Jude’s Children’s Research Hospital, 
Memphis, TN).  Different isolations of p53-/- MEFs were obtained from E. Ruley 
(Vanderbilt University, Nashville, TN) and C. Eischen (Vanderbilt University, 
Nashville, TN).  The ARF-/- MEFs were obtained from C. Sherr (St.Jude’s 
Children’s Research Hospital, Memphis, TN).  DKO, p53-/-, ARF-/-, Rat 1a 
embryonic fibroblasts, and psi2 ecotropic packaging cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM, high glucose; Gibco/Invitrogen) 
containing 10% bovine calf serum (HyClone) supplemented with 100 U/ml 
penicillin and 100 µg/ml streptomycin.  The myc-/- (HO16) and myc+/+ (TGR) Rat 
1a cells were obtained from J. Sedivy (Brown University, Providence, Rhode 
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Island) and have been described previously (Mateyak et al., 1997).  TGR and 
H016 Rat 1a cells were maintained in 10% fetal bovine serum (FBS; Atlanta 
Biologicals) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin.  
The media for stable cell lines expressing c-MycER-puro or c-MycER-hygro was 
supplemented with 2.5 µg/ml puromycin (Calbiochem) or 50 µg/ml hygromycin B 
(Invitrogen) respectively.  All cells were maintained at 37oC in a humidified 5% 
CO2 atmosphere.     
 
Cell transfection and infection 
 All cells were transiently transfected with Lipofectamine 2000 (Invitrogen) or 
FuGENE 6 according to manufacturer’s protocol with the indicated plasmids.  
Details for the luciferase transfections are documented in the ‘Luciferase Assays’ 
section below.  
 The generation of DKO MEFs, p53-/- MEFs, and HO16 Rat 1a cells stably 
expressing c-MycER or vector was described previously (Xiao et al. 1998; Qi et 
al. 2004).  To generate stable ARF-/- MEFs expressing c-MycER, psi2 cells were 
transfected with pBabe-hygro-MycER using FuGENE 6 transfection reagent 
(Roche) and the virus-producing cells were selected in 400 µg/ml hygromycin B 
for approximately 7 days.  The ARF-/- MEFs were then infected for 6 hours with 
viral supernatants, in the presence of 6 µg/ml polybrene, collected from the 
stable psi2 packaging cell line stably expressing c-MycER-hygro.  The infected 
cells were selected for in 400 µg/ml hygromycin B for 2 weeks.  Expression of c-
MycER was verified via Western blotting. 
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Plasmids and expression vectors. 
The expression vectors pRcCMV-Myc, pBabe-puro-MycER, pBabe-hygro-
MycER, htert-luc, and 4x-EMS-luc, obtained from R. Eisenman (Fred Hutchison 
Cancer Research Center, Seattle, Washington) have been previously described 
(Qi et al. 2004).  The 2.5kb Egr1-luc plasmid was constructed by removing the 
Egr1 promoter portion of pBLUECAT-2, obtained from B. Christy (University of 
Texas, San Antonio Texas), with BglII (New England Biolabs) digestion.  It was 
then ligated (Promega) into the multiple cloning site (MCS) of linearized pGL3 
(Promega). All constructs were verified by sequencing through the Vanderbilt 
DNA Sequencing Core.   
 
Cell treatments 
 c-MycER was activated in all cells by the addition of 1-10µM 4-
hydroxytamoxifen (OHT; Sigma) as indicated.  To inhibit protein translation, p53-
/- MEFs expressing c-MycER were treated with 50 µg/ml of cycloheximide 
(Sigma) dissolved in dimethyl sulfoxide (DMSO).  Cessation of protein synthesis 
was confirmed by following the decay of c-Myc protein over time with Western 
blotting.  To inhibit transcription HO16 Rat 1a cells expressing MycER were 
treated with 10 µg/ml Actinomycin D (Sigma) dissolved in ethanol.   
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RNA interference 
The day prior to treatment, p53-/- MEFs expressing c-MycER were 
seeded at 3 x 106 cells per 10cm dish in antibiotic free media.   The cells were 
treated with a final concentration of 100nM of CDKN2A (ARF) SMARTpool or 
Control Pool Non-Targeting #1 siRNA purchased from DHARMACON using 
Dharmafect Reagent 4 according to manufacturer’s instructions.  Approximately 
16 hours later, cells were trypsinized and seeded at 5 x 104 cells per well in a 6 
well dish.  The next day MycER was activated with 5µM 4-hydroxytamoxifen 
(OHT; Sigma) or cells were mock treated with ethanol.  The cells were harvested, 
RNA was isolated, and real time reverse-transcriptase polymerase chain reaction 
(RT-PCR) was preformed as detailed below.  Knock-down of ARF was verified 
via Western blotting.    
 
Antibodies 
 The affinity-purified rabbit polyclonal anti-Mycfl (against full-length murine c-
Myc) has been previously described (Spotts et al. 1997).  The c-Myc rabbit 
polyclonal antibody, N-262x, designed for Chromatin Immunoprecipitation (ChIP) 
applications was purchased from Santa Cruz Biotechnology.  The affinity-purified 
rabbit polyclonal antibody, anti-ARF 754-5 (against murine p19 ARF) was 
purchased from Millipore.  The rabbit polyclonal antibody, anti-CDKN2A (anti-p19 
ARF), used in the ChIP assays was purchased from GeneTex.  The Egr1 rabbit 
polyclonal antibody, anti-Egr1 C-19, was purchased from Santa Cruz 
Biotechnology.  The mouse monoclonal anti-β-actin antibody was purchased 
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from Sigma-Aldrich.  Rabbit IgG used as a control for ChIP assays was 
purchased from Upstate. 
 
Western blot analysis 
Cell lysates were prepared in antibody buffer (20mM Tris pH7.4, 50mM 
NaCl, 0.5% Triton X-100, 0.5% DOC, 0.5% SDS, 1mM EDTA, 0.1M PMSF, 
10mg/ml Aprotinin, 2mg/ml Leupeptin) and sonicated briefly.  Total protein for 
each lysate was calculated using Bio-Rad DC Protein Assay (Bio-Rad).  Equal 
amounts of lysate (50-100 µg of total protein) were boiled for 3 minutes in 
Laemmli sample buffer and were resolved by 10-15% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE).  Molecular weight markers 
(Thermo Scientific and Fermentas Life Sciences) were used as standards in 
each gel.  Proteins were transferred to nitrocellulose membranes (Protran) 
electrophoretically followed by blocking in 3-5% milk in Tris-buffered saline (TBS) 
for 30 minutes before an overnight incubation with the indicated antibodies at 
4oC.  The membranes were washed with TBS and then incubated with 
horseradish peroxidase conjugated anti-rabbit IgG or anti-mouse IgG secondary 
antibodies in 3-5% milk in TBS at a concentration of 1:10,000 for 45 minutes.  
The membranes were washed again in TBS and proteins were detected using 
enhanced chemiluminescence (ECL; Western Lightning) according to the 
manufacturer’s instructions followed by development on chemiluminescence film 
(Amersham Hyperfilm ECL; GE). 
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Quantitative real-time RT-PCR 
MEFs and HO16 Rat 1 cells expressing c-MycER were harvested at the 
indicated times following the activation of c-MycER with 2-5µM OHT.  Total RNA 
was isolated using the RNeasy Mini Kit (Qiagen) and concentration and purity 
was determined using a NanoDrop Spectrophotometer (ThermoScientific). Ten 
µgs of RNA were treated with DNA-free DNase (Ambion) or total RNA was 
treated with the RNase-free DNase set (Qiagen).  Five µg of total RNA were 
reverse transcribed by using the iScript cDNA synthesis kit (Bio-Rad).  
Quantitative real-time PCR was performed with the Bio-Rad iCycler by using iQ 
SYBR Green supermix (Bio-Rad). The specific primer sequences are listed 
below.  A standard curve of 2- or 4-fold dilutions was run with each assay for 
each primer set.  A melting curve was performed at the end of each protocol to 
ensure the production of only one product.  Relative measurement of gene 
expression was calculated following manufacturer's instructions using the 
standard curve method. Briefly, the relative mRNA level was calculated by 
dividing the relative starting quantity (calculated from the standard curve) of each 
experimental gene by the relative starting quantity of a housekeeping gene (β-
actin or TATA-binding protein).  For fold induction, relative mRNA values 
compared with the un-activated control samples were graphed as the mean ± SD 
from triplicate assays.    
For mRNA level analyses in HO16 and TGR cells, the cells were either 
harvested while growing logarithmically, or upon reaching confluence, were 
shifted to media containing 0.1%FBS for 48 hours before stimulation with 20% 
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FBS.  Cells were harvested at the indicated times and the mRNA levels were 
determined as above.  All real-time RT-PCR analyses were performed with the 
primers listed below and the results are reported as the mean +/- the s.d. relative 
to β-actin levels calculated as above. 
 
Chromatin immunoprecipitation 
Sixteen hours after p53-/- MycER and DKO MycER MEFs were plated at 6 
x 106 cells/150mm-dish, they were treated with either 2µM OHT or ethanol for 6 
hours.  The cells were cross-linked for 10 minutes at room temperature by adding 
formaldehyde (Sigma) to a final concentration of 1% directly to the media.  The 
cross-linking reaction was terminated through addition of glycine to a final 
concentration of 0.125M.  The adherent cells were washed two times with 
phosphate buffered saline (PBS; Gibco) scraped, pooled, and pelleted with 
centrifugation at 1000 rpm for 10 minutes at 4oC.  Nuclei were isolated by re-
suspending and incubating the cells in swelling buffer (0.1M Tris pH 7.6, 10mM 
KOAc, 15mM MgOAc, 1% NP40, 1mM PMSF, 0.01mg/ml aprotinin, 0.01 mg/ml 
leupeptin) at a concentration of 1 ml per 5 x 107 cells for 20 minutes on ice 
followed by douncing the cells with 20 strokes in a 1 ml tight dounce 
homogenizer (Wheaton).  Nuclei were collected through centrifugation at 2,500 x 
g for 5 minutes at 4oC and lysed in nuclei lysis buffer (50 mM Tris-Cl pH 8.0, 10 
mM EDTA, 1% SDS, 1mM PMSF, 0.01mg/ml aprotinin, 0.01 mg/ml leupeptin) at 
a concentration of 1 ml per 1 x 108 cells for 10 minutes on ice.  The chromatin 
was sheared through 8-10 pulses of sonication for 20 seconds at 25% power on 
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a Sonics Vibracell VC130 sonicator with 30-second rest intervals on ice between 
pulses.  Agarose gels stained with ethidium bromide confirmed that chromatin 
was largely sheared to between ~100-1000 base pairs.  Sheared chromatin was 
pre-cleared with 10 µl of blocked/washed Staphylococcus aureus (Staph A) cells 
—blocked in 1 mg/ml of salmon sperm DNA and 1 mg/ml of bovine serum 
albumin (BSA) and washed in dialysis buffer (2 mM EDTA, 50 mM Tris-Cl pH 
8.0)— per 1 x 107 cells for 15 minutes at 4oC.   Chromatin from 1-2 x 107 cells 
was immunoprecipitated overnight with 1-2 µg of the indicated antibodies in IP 
dilution buffer (0.01% SDS, 1.1% Triton X 100, 1.2 mM EDTA, 16.7 mM Tris-Cl, 
167 mM NaCl, 10 µl/ml PMSF, 1 µl/ml aprotinin, 1µl/ml leupeptin).  The immune 
complexes were precipitated with blocked/washed Staph A cells (10 µl per 1 x 
107 cells) and washed twice with dialysis buffer supplemented with 0.2% 
Sarkosyl and 4 times with IP wash buffer (100 mM Tris-Cl pH 9.0, 500 mM LiCl, 
1% NP40, 1% deoxycholic acid (DOC) sodium salt, 1 mM PMSF) before elution 
in IP elution buffer (50 mM NaHCO3, 1% SDS).  Samples were supplemented 
with NaCl to a final concentration of 0.2M and incubated at 67oC for 4 hours to 
reverse formaldehyde cross-links.  Samples were RNAse (Clontech) and 
Proteinase K (Clontech) treated to remove RNA and protein respectively before 
DNA was purified with a PCR purification kit (Qiagen) according to 
manufacturer’s protocol.  Purified DNA was subjected to PCR amplification 
(Roche’s Taq polymerase using Promega protocol and buffers supplemented 
with betaine) using specific primer sets listed below.  PCR products were 
subjected to analysis on an ethidium bromide stained 1.5% agarose gel.  For 
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quantitative ChIP analyses, ChIPs were performed as described above except 
the purified DNA was subjected to real-time PCR as described above using the 
primers listed below.  A standard curve was used to calculate the relative starting 
quantity of each sample.  The percent of input was calculated by dividing the 
relative starting quantity from each IP (Myc, ARF, IgG) by the relative starting 
quantity of the input and then by multiplying by 100.  The results are reported as 
the mean +/- the s.d. from triplicate samples.  
 
Luciferase Assays 
p53-/- MEFs and DKO MEFs were transfected with 2 µg of Myc expression 
vector or empty vector, 1.9 µg of reporter plasmid, and 0.1 µg of pRL-TK 
(Promega) Renilla luciferase internal control using Lipofectamine 2000 reagent.  
Luciferase assays were carried out 48 hours post transfection according to the 
manufacturer's instructions (Dual-Luciferase Reporter Assay System; Promega) 
using a single tube luminometer (Pharmingen).  Results were normalized for 
expression of pRL-TK and are reported as the mean ± s.d. from triplicate 
samples.  For the assays in HO16, TGR, and Rat1a cells, 3.9 µg of reporter 
plasmid and 0.1mg of pRL-TK or pRL-SV40 were transfected into the cells.  
Luciferase assays were performed, calculated, and reported as above. 
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Real-time RT-PCR primers 
Egr1 mouse    fwd: 5’ GAGGAGATGATGCTGCTGAG 3’ 
                       rev: 5’ TGCTGCTGCTGCTATTACC 3’ 
Egr1 rat           fwd:  5’ GAGCCCGCACCCAACAGTG 3’ 
                        rev:  5’ TGGGGCTCAGGAAAAATGTCA 3’ 
 Egr2 mouse    fwd: 5’ CCTCCACTCACGCCACTCTC 3’ 
                        rev:  5’ CACCACCTCCACTTGCTCCTG 3’ 
Egr2 rat            fwd:  5’ CGCCACACCAAGATCCACC 3’ 
                        rev:  5’  AGCCCCCAGGACCAGAGG 3’ 
β-actin             fwd:  5’ GCTGTGCTATGTTGCTCTAG 3’ 
                        rev:  5’ CGCTCGTTGCCAATAGTG 3’ 
Elf1a                fwd:  5’ AAAATTGGCTACAACCCCGA 3’ 
                        rev:  5’  CCAACCAGAAATTGGCACAA 3’ 
Tbp rat             fwd:  5’ TGCACAGGAGCCAAGAGTGAA 3’ 
                        rev:  5’ CACATCACAGCTCCCCACCA 3’ 
 
ChIP primers  
Egr1 1 fwd: 5’ CGTGCTGTTCCAGACCCTTGAAAT 3’ 
  rev: 5’ TAGTTGTCCATGGTGGGTGAGTGA 3’ 
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Egr1 2 fwd: 5’ CCGGAACAGACCTTATTTGGGCA 3’ 
  rev: 5’ AAGTTCTGCGCGCTGGGATCTCT 3’ 
Egr1 3 fwd: 5’ AGCCCAGGATGACGGCTGTAGAA 3’ 
  rev: 5’ TCAGGCTCCTGGAAAGCCTAGTAT 3’ 
Egr1 N4 fwd: 5’ TTTCGATTCTGGGTGGTGCATTGG 3’ 
  rev: 5’ TGCGAGCTGGGCTAGGGAA 3’ 
Egr1 5 fwd: 5’ CTCCCGAAATACAACCAGAGACCT 3’ 
  rev: 5’ TTGGCTACTGGTTCTTGGGACACT 3’ 
Egr1 N6 fwd: 5’ TCCCTTTGGGTTGCTTCGGAGATA 3’ 
  rev: 5’ ACGAACCCTGCCCTGTCCTAAAGA 3’ 
Egr1 N7 fwd: 5’ TGGAACCCTGGTTCATGTCTGGAT 3’ 
  rev: 5’ AGGGTAACACTTCCTTCACAGAGC 3’ 
Egr1 10 fwd: 5’ GAGAAAGGAATCCATTGCCTCGTG 3’ 
  rev: 5’ TCTTCTGTGTACCCAGCACCTGTT 3’ 
Egr1 11 fwd: 5’ ACCAGGTGCTAGATTCACCAAGTC 3’ 
  rev: 5’ GGTGAGCGTGTTTCCGAGTGAAAT 3’ 
Egr1 N12 fwd: 5’ ACAGAGACCTTCCTGCCTGTCTTT 3’ 
  rev: 5’ CCACCAAGAAGCTTGCTGTTGCAT 3’ 
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Egr1 N14 fwd: 5’ CTGTTGTTGGTGACTTGGCTCCTT 3’ 
  rev: 5’ CCCAGGAAGAGAGATAACCTAGCA 3’ 
Egr1 15 fwd: 5’ AAAGAGAGTCACTTCCTGAGCCCT 3’ 
  rev: 5’ GCTGGTGGCACACTTCTGTTTACT 3’  
Egr1 16 fwd: 5’ ACTACCATTCGATCTGCTTCAGGC 3’ 
  rev: 5’ TGGGTTTCGTCAGCACCCACAT 3’        
eIF4E       fwd: 5’ AGAGGCCTAAATCCAACTCGGCA 3’ 
                 rev: 5’ AAGGCAATACTCACCGGTTCCACA 3’ 
Egr2          fwd:  5’ CTCCAGTCAGTTCTACCATCATCG 3’ 
                 rev:  5’ TCGGGTTATGCAAATAGAGGTCCC 3’ 
 
qChIP primers 
Egr1 set1 fwd: 5’ CTAACCATCACAAGAACCAACAG 3’ 
  rev: 5’ ACTAATGGCAGGGTCACTTTC 3’ 
Egr1 set2 fwd: 5’ GAGAAAGGAATCCATTGCCTCGTG 3’ 
  rev: 5’ TCTTCTGTGTACCCAGCACCTGTT 3’ 
Egr1 set3 fwd: 5’ ACTACCATTCGATCTGCTTCAGGC 3’ 
rev: 5’ TGGGTTTCGTCAGCACCCACAT 3’        
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Results 
 
Differential induction of Egr1 and Egr2 by activated c-Myc depending on the 
presence of ARF   
To examine whether there are c-Myc target genes that are differentially 
regulated due to the presence of ARF, we performed microarray analyses 
comparing c-MycER (Estrogen Receptor)-inducible gene expression between 
DKO (p53/ARF double knockout) MEFs having no ARF with p53-/- MEFs having 
high levels of endogenous ARF.  We used genetically defined MEFs without p53 
to avoid effects caused by ARF activation of p53.  Gene expression was 
analyzed two hours following activation of the chimaeric c-MycER protein by 
hydroxytamoxifen (OHT) to enrich for direct targets.  Interestingly, through these 
microarray analyses we identified all of the Egr transcription factor family 
members as c-Myc-responsive genes (Table 2-1).  Two of the family members 
(Egr2 and Egr3) were up-regulated by c-Myc in DKO-MycER MEFs, but not in 
p53-/- MycER MEFs, suggesting that they are induced by c-Myc only in the 
absence of ARF, which was previously observed for the canonical c-Myc target 
genes nucleolin, eIF4E, and htert (Qi et al. 2004).  Surprisingly, the other two 
family members (Egr1 and Egr4) were up-regulated by c-Myc in p53-/- but not 
DKO-MycER MEFs, suggesting that their inductions are dependent on ARF 
expression.  The differential regulation of Egr1 and Egr2 in p53-/- and DKO-
MycER MEFs following c-Myc activation was verified by real-time RT-PCR (Fig. 
2-1A).       Further,   time   course   analyses   of   Egr1   induction   by   c-MycER  
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Table 2-1. Egr factors are potential ARF-dependent targets of c-Myc. 
Microarray analysis of the Egr family members in p53-/- and DKO MycER MEFs. 
The values represent the relative expression after two hours of Myc activation in 
the indicated cell line compared to mock treatment in the same cells. 
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demonstrated that Egr1 mRNA levels were induced by c-Myc within 1-2 hours in 
the p53-/- MycER (high levels of ARF) MEFs, but not in the DKO-MycER (no 
ARF) MEFs (Fig. 2-1B).  Conversely, Egr2 mRNA levels were induced in the 
DKO, but not the p53-/- MycER MEFs with a maximal induction approximately at 
2 hours (Fig 2-1C).  Additionally, we confirmed the induction of Egr1 mRNA 
levels by c-Myc in another cell line, c-myc-/- Rat1 fibroblasts (H016) expressing c-
MycER.  The c-myc-/- cell line was chosen to remove the effects of endogenous 
c-Myc on the control of Egr1 mRNA levels and because they have low levels of 
ARF expression (Qi et al. 2004).  Again, real-time RT-PCR confirmed that Egr1 
levels are increased by OHT activation of c-MycER, but not by mock treatment in 
cells that have ARF expression (Fig 2-2), suggesting that this induction is not 
cell-type specific. 
 
ARF is necessary for c-Myc to induce Egr1 
Differential regulation of Egr1 and Egr2 by c-Myc in the presence of ARF 
suggests different mechanisms of induction and biological outcomes.  Since ARF 
is essential for p53-independent c-Myc-induced apoptosis, the ARF-dependent 
Egr1 putative target gene was further characterized.  To determine the necessity 
of ARF for induction of Egr1 by c-Myc, ARF protein expression was silenced by 
siRNA, as confirmed by immunoblot analysis, in p53-/- MycER MEFs (Fig. 2-3, 
lower panel).  Egr1 induction by c-Myc activation was reduced at 2 hours, the	  
time of maximal induction, in the ARF siRNA treated cells compared to cells 
treated   with   control   siRNA   (Fig. 2-3, upper panel),   suggesting  that  ARF  is 	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Figure 2-1. c-Myc differentially induces Egr1 and Egr2 depending on the 
presence of ARF. (A) Microarray verification by real-time RT-PCR of Egr1 and 
Egr2 mRNA levels following 2 hrs of OHT treatment in p53−/− and DKO MycER 
MEFs. (B and C) Time course analyses following MycER activation of mRNA 
levels of Egr1 (B) and Egr2 (C) in p53−/− and DKO MycER MEFs (± OHT) as 
measured by real-time RT-PCR. Results are reported as the mean of the relative 
mRNA levels of Egr1 or Egr2 to β-actin at each time point normalized to time 0 to 
give the relative fold induction ± standard deviation. 
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Figure 2-2.  c-Myc induces Egr1 mRNA levels in Rat1 cells.  Real time RT-PCR 
analysis of mRNA levels of Egr1 mRNA in c-myc-/- (HO16) cells expressing MycER 
following activation or mock treatment with OHT and ethanol respectively. Results 
are reported as the mean of the relative mRNA levels of Egr1 to β-actin at each 
time point normalized to time 0 to give the relative fold induction ± standard 
deviation.	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necessary for c-Myc driven Egr1 induction.  This reinforces the results in the 
genetically defined fibroblasts by providing evidence that the difference between 
the inductions of Egr1 in the DKO and p53-/- MEFs by activation of c-Myc was 
due to the lack or presence of ARF and not a different accumulated genetic 
abnormality. 	  
	  
Egr1 is a direct target gene of c-Myc 
 The relatively rapid induction of Egr1 mRNA in p53-/- MycER MEFs by 
activated c-MycER suggests that it is a direct target.  To test if c-Myc can induce 
Egr1 mRNA levels in the absence of protein synthesis, p53-/- MycER MEFs were 
treated with cycloheximide to inhibit translation before c-MycER activation.  
Cycloheximide treatment alone caused Elf1a, a gene not regulated by c-Myc 
(Knoepfler et al. 2006), and Egr1 mRNA levels to stabilize (data not shown), as 
previously observed with many transcripts (Lemaire et al. 1988).  However, 
activation of c-MycER in the presence of cycloheximide increased Egr1 levels by 
~4 fold in two hours over cycloheximide treatment alone, suggesting that c-Myc 
can induce Egr1 without de novo protein synthesis (Fig. 2-4, upper panel), even 
with relatively modest levels of c-MycER remaining (Fig. 2-4, lower panel).  In 
contrast, activated c-MycER did not enhance levels of Elf1a, a gene known not to 
be regulated by c-Myc, in the presence or absence of cycloheximide (Fig. 2-4).  
This suggests that Egr1 is a direct transcriptional target of c-Myc.  However, c-
Myc may also control the levels of Egr1 by other mechanisms, such as inhibition 
of  mRNA  degradation.   To  determine  whether  c-Myc  influenced  Egr1 mRNA  
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Figure 2-3.  ARF is necessary for the c-Myc induction of Egr1. (top panel) 
Real-time RT-PCR analysis of Egr1 mRNA levels following c-Myc activation with 
OHT for two hours in p53-/- MycER MEFs treated first for 48 hours with either siARF 
or control SMART pool.  Results are reported as the mean of the relative mRNA 
levels of Egr1 to β-actin at each time point normalized to time 0 to give the 
relative fold induction ± standard deviation.  (lower panel) Immunoblot showing 
ARF protein levels following siRNA treatment.  	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Figure 2-4. c-Myc induces Egr1 mRNA in the absence of protein synthesis.  
Real-time RT-PCR analysis of Egr1 or Elf1a in p53-/-MycER MEFs (+/-OHT 2hrs) 
treated first with cycloheximide—or mock treated with DMSO—for 30 minutes to 
inhibit protein synthesis.  Results are graphed as the mean of the relative mRNA fold 
induction over mock treated (ETOH) controls +/- s.d.  Immunoblot shows c-Myc and 
c-MycER protein following cycloheximide addition. 
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degradation, real-time RT-PCR analysis was performed following transcriptional 
inhibition with actinomycin D treatment in c-myc-/- (H016) cells expressing c-
MycER.  The decay of Egr1 mRNA levels was the same with c-MycER activation 
or mock treatment (Fig. 2-5).  Therefore, activation of c-MycER primarily 
increases transcription of Egr1 in cells with ARF expression, rather than 
enhancing Egr1 mRNA stability.     	  
	  
Egr1 protein induction by c-Myc	  
 In order to demonstrate that the regulation of Egr1 mRNA levels by 
activated c-Myc correlates with protein levels, we examined the effects of c-Myc 
activation on Egr1 protein expression through Western Blotting (WB).  
Immunoblot analyses revealed that activated c-MycER induced the expression of 
Egr1 protein in p53-/- MycER MEFs within 3-4 hours, with maximal induction by 8 
hours (Fig. 2-6A), but failed to induce Egr1 levels in ARF-/- MycER MEFs (Fig. 2-
6B).  Egr1 levels were also not induced by OHT treatment alone in p53-/- MEFs 
with vector (Fig. 2-6D), nor by activated c-MycER in DKO MEFs (Fig. 2-6C), 
indicating that Egr1 protein levels are only increased by activated c-Myc in the 
presence of ARF.  	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Figure 2-5.  c-Myc does not influence the stability of Egr1 mRNA.  Real time 
RT-PCR analysis of the decay of Egr1 mRNA levels in HO16 cells expressing c-
MycER (+/-OHT) at the indicated times following 15 minutes of actinomycin D 
treatment to prevent transcription.  Results are reported as the mean of the 
relative mRNA levels of Egr1 to β-actin at each time point divided by the original 
amount at time 0 and multiplied by 100 to give the percent mRNA remaining.   
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Figure 2-6.  Activation of c-Myc induces Egr1 protein levels only in the 
presence of ARF. (A-C) Western blot (WB) analyses of Egr1 protein levels 
following OHT activation in p53-/- MycER MEFs (A), ARF-/- MycER MEFs (B), and 
DKO MycER MEFs. (D) WB analyses of Egr1 protein levels after the indicated times 
following OHT treatment in p53-/- MEFs with vector instead of MycER to 
demonstrate that Egr1 protein is not induced by OHT treatment alone.  A WB 
analysis of β-actin expression demonstrates equal loading for each cell type and 
time point.  
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Endogenous c-Myc regulates Egr1 levels.  	  
 Thus far in this chapter, we have shown that the activation of an exogenously 
expressed c-MycER directly induces the mRNA and protein levels of Egr1 only in 
cells with ARF.  To determine whether endogenous c-Myc also regulates Egr1 
expression, logarithmically growing c-myc-/- (HO16) and parental wild-type (TGR) 
Rat1 cells were harvested and the relative expression of Egr1 and the negative 
control Elf1a was determined with real-time RT-PCR.  Egr1 was expressed 
substantially higher in the cells with c-Myc, unlike Elf1a, which was expressed 
equally in the two cell lines (Fig. 2-7A), suggesting that Egr1 expression is controlled 
by endogenous c-Myc.  	  
 Since the Egr genes are also known to be immediate early genes like c-
Myc that are induced by serum (Christy and Nathans 1989), we examined the 
influence of endogenous c-Myc expression on the serum induction of Egr1.  The 
TGR and HO16 cells were made quiescent by serum deprivation and then the 
expression of Egr1 was followed after serum stimulation.  Egr1 levels were 
substantially increased and sustained to a greater extent in the cells with c-Myc 
compared to cells without c-Myc (Fig. 2-7B).  These results suggest that Egr1 gene 
expression is controlled by endogenous c-Myc and that c-Myc is necessary for 
the full serum induction of Egr1. 
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Figure 2-7.  Endogenous c-Myc is necessary for the full expression and 
induction of Egr1.  (A) Real-time RT-PCR analysis of Egr1 mRNA levels in 
logarithmically growing c-myc-/- (H016) and parental (TGR) rat1 cells.  (B) Real-time 
RT-PCR analysis of Egr1 mRNA levels following serum stimulation of serum-starved 
H016 and TGR cells. Results are graphed as the mean of the relative mRNA levels 
of Egr1 to TATA binding protein (Tbp) +/- s.d. 
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c-Myc and ARF are recruited to the Egr1 promoter 
 If Egr1 is a direct target as suggested by the preceding data, then c-Myc 
must be recruited to the Egr1 promoter.  However, since the proximal promoter of 
Egr1—at least 15 kilobases upstream and downstream of the transcriptional start 
site—does not contain any canonical E-box Myc sites (CACGTG), we used a 
scanning chromatin immunoprecipitation (ChIP) approach to identify the c-Myc 
binding region.  ChIP was performed using p53-/- MycER MEFs with partially 
overlapping primers spanning 5 kilobases (kbs) upstream of the start site.  We 
found that activated c-Myc was recruited to one region of the Egr1 promoter (-
904 to -1319) (Fig. 2-8).  As a positive control, primers for the c-Myc canonical 
target gene eIF4E promoter were used (Fig. 2-8).  Since Egr1 induction by c-
MycER is dependent on the presence of ARF, we determined whether ARF is 
also recruited to the Egr1 promoter.  ChIP analysis revealed that ARF was 
recruited to the same region as c-Myc upon OHT activation, but not to other 
regions of the promoter (Fig. 2-9A, right panel).  However, ARF was not detected 
at the Egr1 promoter without OHT activation (Fig. 2-9A, left panel), suggesting 
that ARF is only recruited to the Egr1 promoter upon c-Myc activation, as 
previously observed with canonical target genes (Qi et al. 2004).  This 
observation agrees with the finding that ARF is mostly nucleolar in p53-/- MEFs 
until c-Myc activation causes ARF to be translocated to the nucleoplasm (Qi et al. 
2004; Gregory et al. 2005).  Conversely, to determine whether c-Myc can be 
recruited to the Egr1 promoter without ARF we used DKO-MycER MEFs.     ChIP  
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Figure 2-8.   c-Myc is recruited to the Egr1 promoter at a noncanonical binding 
site. Chromatin prepared from p53-/- MycER MEFs (+OHT) was subjected to IP 
using anti-Myc or IgG followed by PCR using the indicated panel of partially 
overlapping primers spanning 5kb of the Egr1 promoter.  The box indicates a region 
(-904 to -1319) to which c-Myc is recruited.  eIF4E primers spanning an 
established EMS binding sequence were used as a positive control.  The 
numbers on the left indicate primer pairs amplifying a specific region of the 
promoter referred to in Figure 2-9. 
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analysis revealed that activated c-MycER was recruited to the Egr1 promoter 
without ARF (Fig. 2-9B, right panel), suggesting that although ARF cannot 
associate with the Egr1 promoter without Myc that Myc can associate without 
ARF.   
 To quantitatively determine the relative amounts of c-Myc and ARF 
recruited to the Egr1 promoter under different conditions, we used real-time PCR 
to analyze the ChIP assays.  We verified that c-Myc and ARF were both recruited 
to the Egr1 promoter after MycER activation, but ARF was not detected without 
activation of c-Myc in p53-/- MycER MEFs (Fig. 2-9C).  Without ARF, activated c-
MycER was still recruited to the Egr1 promoter in DKO-MycER MEFs (Fig. 2-9D), 
but at lower levels compared to p53-/- MycER MEFs (Fig. 2-9C), suggesting that 
ARF enhances the recruitment of c-Myc to the Egr1 promoter.  Without OHT 
activation we detected low levels of c-Myc at the Egr1 promoter in p53-/- MycER 
MEFs (Fig. 2-9C), but not in DKO-MycER MEFs (Fig. 2-9D), suggesting that c-
MycER is partially active without OHT in the p53-/- MycER MEFs.  Taken 
together, the results suggest that the interaction of activated c-Myc with ARF 
enhances the recruitment of c-Myc to the Egr1 promoter, but that ARF alone 
cannot be detected. 
 In contrast to Egr1, Egr2 is induced by c-MycER in DKO-MycER MEFs 
and the Egr2 promoter contains three putative canonical CACGTG sites.  ChIP 
analysis using DKO-MycER MEFs revealed that activated c-Myc was recruited to 
the canonical CACGTG in the Egr2 promoter located at -2400 (Fig. 2-10A), but 
not to the other two CACGTG sequences.  As a positive control, primers for the  
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Figure 2-9.  ARF is recruited with c-Myc to the Egr1 promoter.  (A) ChIP 
performed as in Fig. 2-8 except MycER was either activated with OHT treatment 
(right panel) or mock treated with ethanol (left panel) for 6 hours and chromatin was 
subjected to IP with anti-Myc, anti-ARF, or IgG.  (B) Chromatin prepared from DKO 
MycER MEFs (+/-OHT) was subjected to IP using anti-Myc, IgG, or no antibody 
followed by PCR using the indicated primers that span the binding site in the 
Egr1 promoter.  (C) ChIPs as in (A) in p53-/- MycER MEFs  +/- OHT except purified 
DNA was subjected to real-time PCR.  Results are reported as the mean of the 
percent of input +/- s.d.  The numbers below the x-axis indicate the region of the 
Egr1 promoter being amplified as demonstrated in Fig. 2-8 and (A).  (D) Quantitative 
ChIPs as in (C) but in DKO MycER MEFs +/- OHT. 
 
 
 
 
 
 
 49	  
 
 
 
 
 
 50	  
established c-Myc target eIF4E promoter were used (Fig. 2-10B).  This suggests 
that like Egr1, Egr2 is also a direct target of c-Myc. 
  
c-Myc and ARF regulate the Egr1 promoter 
 To further examine the regulation of the Egr1 promoter by c-Myc and ARF 
we performed luciferase assays with a 2.5kb fragment of the Egr1 promoter 
containing the putative c-Myc binding site identified above.  The Egr1 promoter 
was induced in p53-/- MEFs overexpressing c-Myc (Fig. 2-11A), demonstrating 
that c-Myc activates the Egr1 promoter.  In contrast, the Egr1 promoter was 
slightly inhibited in DKO MEFs expressing c-Myc (Fig 2-11B), confirming the 
dependence on ARF for the c-Myc activation of the Egr1 promoter.  As previously 
reported (Qi et al. 2004), the htert promoter and the 4XEMS promoter were both 
induced by c-Myc in DKO MEFs (Fig. 2-11B), but the htert promoter induction 
was blocked in p53-/- MEFs with high ARF expression (Fig. 2-11A).  In addition, 
the Egr1 promoter was induced by c-Myc in Rat1a cells (Fig. 2-11C), confirming 
that this regulation is not cell-type specific.  To determine whether the Egr1 
promoter is regulated by endogenous c-Myc, the activity of the Egr1 luciferase 
promoter was compared between TGR (c-myc WT) and HO16 (c-myc-/-) Rat1 
cells.  The Egr1 promoter was more active in TGR cells than in the HO16 cells, 
similar to the levels observed with the artificial canonical 4XEMS promoter (Fig. 
2-11D).  In comparison to the endogenous Egr1 expression induced by c-MycER 
(Fig. 2-11B) the activity of the Egr1 promoter induced by c-Myc in transient 
luciferase assays is relatively modest, suggesting that the chromatin environment  
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Figure 2-10. c-Myc is recruited to the Egr2 promoter at a canonical binding 
site. (A-B) Chromatin prepared from DKO MycER MEFs (+OHT) was subjected to 
ChIP using anti-Myc or IgG followed by PCR amplification using primers spanning 
the EMS of (A) eif4E and the (B) 3 EMS sites in the Egr2 promoter gel.    
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Figure 2-11. c-Myc activates the Egr1 promoter in the presence of ARF.  (A-
B) Reporter constructs for Egr1 (2.5kb upstream), htert, and 4XEMS promoters 
were transiently transfected into p53-/- MEFs (A) and DKO MEFs (B) with 
exogenous c-Myc or vector control and a thymidine kinase renilla luciferase 
(pRL-TK) transfection control.  The mean of the relative luciferase reporter 
activity to pRL-TK is reported +/- s.d. (C) The Egr1 reporter construct and pRL-
TK were transfected into Rat1A cells that constitutively express c-Myc or vector.  
Relative luciferase activity was determined as above and then normalized to the 
vector control.  (D) The Egr1 reporter construct or 4xEMS were transfected into 
c-myc-/- (H016) and WT (TGR) cells and relative luciferase activity was 
determined and results were normalized to the activity in c-myc-/- cells.   
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and/or the different assay conditions influence the regulation of the Egr1 
promoter by c-Myc.  Taken together these results suggest that both exogenous 
and endogenous c-Myc induce the Egr1 promoter by a novel ARF-dependent 
noncanonical transcriptional mechanism, unlike other c-Myc target gene 
promoters containing the canonical CACGTG binding site that are inhibited by 
ARF. 
 
Loss of N-terminal ubiquitination mimics ARF control of c-Myc-Induced Egr1 
expression.  
 In collaboration with Dr. Q. Zhang and Dr. M. Gregory, we observed that 
the interaction with ARF reduced N-terminal ubiquitination of c-Myc (Zhang and 
Gregory, unpublished observations). Because there is evidence from several 
labs that ubiquitin plays a role in transcription beyond its function in proteolysis 
(Kim et al. 2003; von der Lehr et al. 2003) and because our data demonstrate 
that ARF binding simultaneously influences c-Myc ubiquitination and 
transcriptional regulation, we hypothesized that ARF may affect c-Myc 
transcriptional functions by preventing N-terminal ubiquitination.  To determine 
whether inhibiting ubiquitination of the N-terminal transcriptional regulatory 
domain (TRD) affects c-Myc mediated transcription, we generated a full-length 
expression vector of c-MycER that has all six lysines (51, 52, 127, 144, 149 and 
158) in the TRD changed to arginines (Figure 2-12), which we termed c-
MycN6KR-ER.   
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 We first examined the effects of our mutant on c-Myc ubiquitination, and the 
c-MycN6KR-ER is less ubiquitinated compared with wild-type c-Myc.  Next, we 
tested the effects of inhibiting N-terminal ubiquitination on c-Myc transcription in 
MEFs without ARF.  In DKO MEFs wild-type c-MycER induced the well-
characterized canonical c-Myc target genes nucleolin, eIF4E and Rcl, in the 
typical fashion, whereas c-MycN6KR-ER, which lacks the 6 lysines in the N-
terminal TRD, was unable to induce their expression (Figure 2-13A-C) much like 
wild-type c-Myc cannot induce canonical targets when interacting with ARF.  In 
marked contrast, c-MycN6KR-ER was able to induce Egr1 expression, even 
without ARF, to significantly higher levels than wild-type c-MycER (Figure 2-
13D).   Taken together, these results suggest that the loss of c-Myc N-terminal 
ubiquitination mimics the effects of the ARF interaction on c-Myc-driven 
transcription.  When either c-Myc binds to ARF, or in the absence of ARF, when 
N-terminal ubiquitination of c-Myc is prevented through mutation, then c-Myc no 
longer induces canonical target genes, but instead induces Egr1.  Therefore, this 
suggests that a possible mechanism for ARF control on the transcriptional 
activities of c-Myc is through preventing the ubiquitination of the TRD of c-Myc.  
 
Discussion 
 
Our results suggest that there is a novel ARF-dependent mechanism of c-
Myc transcriptional regulation, whereby ARF binds with c-Myc at promoters and 
selectively   and   differentially   induces   c-Myc   target   genes.   Previously,  we  
 56	  
 
 
 
 
 
 
Figure 2-12. Diagrammatic representation showing c-Myc protein structure 
and lysines mutated in MycN6KR. Sites of N-terminal lysine residues mutated 
in MycN6KR are shown.  The sites of interactions of known N-terminal E3 
ubiquitin ligases Fbw7 and Skp2 are indicated below the diagram.  Numbers 
under diagram indicate relative amino acid position of specific domains. Notable 
sequence motifs are denoted on the diagram. The relative position of an 
alternative translation initiation site, c-MycS, is shown on the bottom of the 
diagram. 
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Figure 2-13. MycN6KR induces Egr1 but not canonical c-Myc target genes 
in cells without ARF.  Serum starved DKO MEFs expressing MycER or 
MycN6KR-ER were induced with OHT.  RNA was isolated at the indicated times 
and was reverse transcribed using the RT-PCR system (Promega).  Quantitative 
real-time PCR was performed using the iCycler and SYBR green dye (Bio-Rad) 
with primers for (A) eif4E, (B) nucleolin, (C) rcl, and (D) egr1.  Relative 
measurement of gene expression was calculated following manufacturer’s 
instructions using the standard curve method.  Relative mRNA levels compared 
to β-actin mRNA were graphed as the mean ±s.d. from triplicate assays. 
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demonstrated that ARF inhibits well-established target genes with canonical Myc 
binding sites (Qi et al. 2004), as exemplified by Egr2 shown in this chapter.  In 
contrast, we have now established that ARF is necessary for c-Myc to directly 
induce transcription of a novel target gene, Egr1.  This is the first c-Myc target 
gene that has been shown to be dependent on ARF.  Although the regulation of 
any c-Myc target gene may be cell-type specific, Egr1 was also recently found to 
be induced by c-Myc in a microarray using B cells (Fan et al. 2010).  	  
 Since c-Myc is recruited to the Egr1 promoter without ARF, albeit at lesser 
amounts than with ARF, we propose that ARF may not only enhance recruitment 
of c-Myc to the Egr1 promoter, but also influences the transcriptional activity of c-
Myc target genes post-DNA binding.  Substantial control of c-Myc target genes 
after DNA binding is supported by the previous observation that c-Myc was 
directly recruited to approximately 3,000 genes in human B cells, but only 406 
were induced by activated c-Myc (Zeller et al. 2006).  Influencing the 
transcriptional up-regulation of a c-Myc target gene promoter by interaction with 
ARF may involve a number of mechanisms, including modulating RNA 
polymerase elongation, chromatin modification/remodeling, and/or derepression.  
Unfortunately, how ARF influences c-Myc transcription remains unknown, 
however in this chapter we demonstrate that ARF reduces N-terminal 
ubiquitination of c-Myc.  We further show that this change in post-translational 
modification results in the same differential induction of targets genes—Egr1 is 
induced, while canonical targets are not—observed after the interaction of c-Myc 
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with ARF.  Whether or not the differential induction of targets is important for the 
biological effects exerted by the Myc/ARF interaction will be the focus of Chapter 
III.  Specifically, we will address whether or not the ARF-dependent induction of 
Egr1 is necessary and sufficient for c-Myc-induced p53-independent apoptosis.  
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CHAPTER III 
 
EGR1 IS NECESSARY FOR C-MYC-INDUCED P53-INDEPENDENT 
APOPTOSIS 
 
Introduction 
 Hyperproliferation and transformation as a result of oncogenic c-Myc 
signaling is limited by the simultaneous sensitization of cells to apoptosis by that 
same c-Myc signaling (Nilsson and Cleveland 2003).  As discussed in the 
previous chapters, c-Myc is known to induce apoptosis by increasing p53 levels 
through the induction of the tumor suppressor ARF (Sherr 1998).  Through a 
p53-independent mechanism, ARF also directly inhibits the ability of Myc to 
induce hyperproliferation and transformation, while synergizing with Myc to 
induce apoptosis (Qi et al. 2004).  In the preceding chapter, we demonstrated 
that the interaction with ARF switched the induction of c-Myc targets.  In the 
presence of ARF, Egr2 and canonical target genes were inhibited, while ARF 
expression was necessary for c-Myc to induce Egr1.  In this chapter, we show 
that the differential induction of target genes caused by the ARF interaction is 
necessary for c-Myc to induce apoptosis.  Specifically we demonstrate that the 
ARF-dependent direct c-Myc target gene Egr1 is necessary and sufficient for 
p53-independent c-Myc-induced apoptosis.  
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Materials and Methods 
 
Cell culture 
 In addition to the cell lines described in the preceding chapter, we obtained 
Egr1-/- and wild-type (WT) MEFs from D. Mercola (University of California, Irvine, 
California) and E. Adamson (Burnham Institute, La Jolla, California).  They were 
maintained in 10% fetal bovine serum (FBS; Atlanta Biologicals) supplemented 
with 100 U/ml penicillin and 100 µg/ml streptomycin.  The media for stable cell 
lines expressing c-MycER-puro or c-MycER-hygro was supplemented with 2.5 
µg/ml puromycin (Calbiochem) and 50 µg/ml hygromycin B (Invitrogen) 
respectively.  All cells were maintained at 37oC in a humidified 5% CO2 
atmosphere.     
 
Retroviral infection 
 To generate stable cell lines of Egr1-/- and wild-type MEFs expressing c-
MycER or vector, psi2 cells seeded at 6 x 105 cells/60mm dish were transfected 
with 2µg of pBabe-puro-MycER using 6µl of FuGENE 6 transfection reagent 
(Roche) and the virus-producing cells were selected in 400 µg/ml hygromycin B 
for approximately 7 days.  The Egr1-/- and WT MEFs were then infected for 6 
hours with viral supernatants, in the presence of 6 µg/ml polybrene, collected 
from the psi2 packaging cell line stably expressing c-MycER-puro.  The infected 
cells were selected for in 400 µg/ml hygromycin B for 3 weeks.  Expression of c-
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MycER was verified via Western blotting.  p53-/- MEFs expressing Egr1ER were 
also generated using the above protocol.  
 
Plasmids and expression vectors. 
In addition to the constructs described in the preceding chapter, pCB6-HA-
Egr1 was obtained from J. Svaren (Waisman Center, Madison, Wisconsin). 
pBabepuro-Egr1ER was constructed by first removing the silent restriction sites 
in pCB6-HA-Egr1 with mutagenesis PCR (Stratagene).  Next, using PCR the HA 
tag and the stop codon were removed and an optimal start codon consensus 
sequence was added, as were BamHI restriction sites to both the N and C-
termini.  pBabepuro-MycER was digested with BamHI to remove c-Myc.  The 
amplified product was also digested with BamHI and ligated into pBabe-puro-ER.  
The construct was verified by sequencing.  
 
Cell treatments 
 c-MycER was activated in all cells by the addition of 1-2µM OHT as 
indicated.  Egr1ER was activated in cells by the addition of 1-2µM OHT. As a 
positive control to induce apoptosis, p53-/- MEFs expressing MycER were 
treated with 1µM of staurosporine (Upstate) dissolved in dimethyl sulfoxide 
(DMSO).  
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RNA Interference 
The day prior to treatment p53-/-, ARF-/-, DKO, and wild-type MEFs 
expressing c-MycER were seeded at 4.5 x 106 cells per 10cm dish in antibiotic 
free media.   The cells were treated with a final concentration of 100nM of Egr1 
SMARTpool or Control Pool Non-Targeting #1 siRNA purchased from 
DHARMACON using Dharmafect Reagent 4 according to manufacturer’s 
instructions.  Approximately 16 hours later, cells were trypsinized and seeded as 
described in the apoptosis assay section below.  In order to knock-down 
expression of Egr1 and ARF simultaneously, p53-/- MEFs expressing c-MycER 
were seeded at 3 x 106 cells per 10cm dish in antibiotic free media.  The 
following day cells were treated with a final concentration of 50nM of Egr1 
SMARTpool and 50nM of CDKNDA SMARTpool using Dharmafect Reagent 4 
according to manufacturer’s protocol.  For the treatment of cells with individual 
siRNAs, p53-/- MEFs expressing MycER, seeded at 2x106 cells per 10cm dish, 
were treated with a final concentration of 100nM of each individual siRNA used to 
make the Egr1 SMARTpool, as well as, Control Pool Non-Targeting #2 
purchased from DHARMACON using Dharmafect Reagent 4 according to 
manufacturer’s instructions.  The effectiveness of the siRNA treatments to reduce 
protein expression was determined by Western Blotting.    
 
Antibodies 
 All antibodes used were described in Chapter II. 
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Western blot analysis 
Western blotting was performed as in Chapter II. 
 
Apoptosis assays 
Two days after plating Egr1-/- MycER and WT MycER MEFs at 1x105 
cells/well in 6 well dishes, the cells were shifted into media containing 0.5% FBS 
with or without 2µM OHT (added daily).  The numbers of floating (apoptotic) and 
attached (living) cells were determined in triplicate at the indicated times with a 
hemacytometer.  Results are reported as a ratio of dead to living cells over time.  
To confirm the viability of the cells being counted, one part cell suspension was 
mixed with one part 0.4% Trypan blue (Sigma-Aldrich) before counting.  
For cell death assays performed on RNAi treated cells, p53-/- MycER, 
ARF-/- MycER, DKO-MycER, and WT-MycER MEFs were treated with siRNA as 
described in the RNA interference section above.  After 16-24hrs the cells were 
seeded 2x105 cells/well in 6 well dishes in media containing 2% CS with or 
without 2µM OHT (added daily).  The numbers of living and dead cells were 
determined after three days of OHT treatment as described above in triplicate in 
at least three different experiments with two different polyclonal cell lines and 
reported as the number of dead cells/number of total cells multiplied by 100 
(percent dead).   
For the cell viability assays in p53-/- MEFs expressing Egr1ER or vector, 
the cells were seeded at 2x105 cells/well in 6 well dishes in media containing 
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10% calf serum.  The next day the media was replaced with low serum media 
containing 2% calf serum with 2µM OHT or ethanol.  OHT or ethanol was added 
daily for three days before the number of living and dead cells were determined 
and reported as above.   
Apoptosis was confirmed with an activated caspase-3 colorimetric assay 
(Sigma-Aldrich) according to manufacture protocol.  Briefly, p53-/- MEFs 
expressing c-MycER were treated with siEgr1 or siControl as described above.  
The next day the cells were seeded at 1.2 x 106 cells per 10cm dish in media 
containing 2% calf serum with 2µM OHT (added daily) or ethanol as a control. 
After the third day of c-MycER activation, the cells were washed, lysed, and 
treated according to protocol.  The amount of p-Nitroaniline released due to the 
hydrolysis of acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) by caspase 3 
in the lysate was determine by reading the absorbance values at 405 nm after a 
19 hr incubation at 37oC.  The average caspase 3 activity, determined according 
to manufacturer instructions, was reported +/- the standard deviation from three 
independent samples.	  	  	  	   
 
Results 
 
Egr1-/- MEFs are deficient in c-Myc-induced apoptosis 
 Since c-Myc induces both apoptosis and Egr1 expression in an ARF-
dependent manner, and because Egr1 is necessary for apoptosis in several cell 
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types (Virolle et al. 2001; Yu et al. 2007), we examined whether Egr1 might be 
involved in p53-independent c-Myc-mediated apoptosis.  We obtained Egr1-/- 
MEFs and parental wild-type (WT) MEFs and generated lines that express 
comparable levels of c-MycER (Fig. 3-1, lower panel) through retroviral infection.  
Activated c-MycER induced apoptosis in the WT MEFs, as others have shown, 
but failed to induce apoptosis in the Egr1-/- MEFs, suggesting that Egr1 
expression is necessary for c-Myc-induced apoptosis (Fig. 3-1, upper panel).   
 
Reduced Egr1 and/or ARF expression inhibits c-Myc induced p53-independent 
apoptosis.   
 To confirm the necessity of Egr1 for c-Myc induced apoptosis using 
another approach, we treated p53-/- MycER MEFs with Egr1 siRNA or control 
siRNA.  Egr1 protein expression was effectively inhibited by Egr1 siRNA for up to 
5 days—longer than the duration of an apoptosis assay—with or without OHT 
treatment (Fig. 3-2).  Inhibiting Egr1 expression significantly reduced c-Myc-
induced apoptosis in p53-/- MycER MEFs using a pool of Egr1 siRNA oligomers 
(Fig. 3-3).  In addition, to confirm the necessity of ARF for p53-independent c-
Myc-induced apoptosis, we inhibited ARF protein expression using ARF siRNA 
as performed in Chapter II.  The reduction of c-Myc-induced apoptosis by 
inhibition of ARF expression was comparable to the reduction observed with 
inhibition of Egr1 expression (Fig. 3-3).  Additionally, the combined inhibition of 
both ARF and Egr1 expression did not further reduce c-Myc-induced apoptosis  
(Fig. 3-3),  suggesting that ARF and Egr1 function in the same pathway to induce 
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Figure 3-1.  Activated c-Myc cannot induce cell death in Egr1-/- MEFs.    
Egr1-/- and parental wild-type MEFs expressing equal levels of c-MycER (lower 
panel) were assayed for cell viability (+/-OHT) in low serum (0.5% calf serum) by 
counting living and dead cells with a hemacytometer. Viability was confirmed using 
trypan blue exclusion.  The results are reported as the mean of the ratio of dead to 
living cells from three independent assays +/- standard deviation. 
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Figure 3-2.  siRNA treatment suppresses Egr1 protein for 5 days and 
following MycER activation. Western Blot analysis of Egr1 protein at the 
indicated times in p53-/- MycER MEFs (+OHT on day 2) following treatment with 
either a siEgr1 SMARTpool or a negative control SMARTpool #1 as described in 
Materials and Methods. 
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apoptosis.  Our results demonstrating that c-Myc induces Egr1 only in the 
presence of ARF, also suggests that ARF and Egr1 are functioning in the same 
pathway.  Reduced apoptosis due to loss of Egr1 expression was confirmed by a 
decrease in caspase-3 activation (Fig. 3-4) as determined by a colorimetric assay 
that measures the hydrolysis of acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-
pNA) by activated caspase 3 isolated from cell lysates of treated cells. 
 In order to verify that the reduction of Egr1 through siRNA reduces 
apoptosis in another way, the different Egr1 siRNA oligomers from the pool were 
used to individually knockdown Egr1 expression.  Three of the four oligos 
significantly reduced Egr1 expression as confirmed by Western Blotting (Fig. 3-5, 
lower panel).  The two most efficient oligos (termed C1 and C3) were used to 
treat p53-/- MycER MEFs independently before assaying for apoptosis in low 
serum with or without activation of MycER with OHT.  As was the case with the 
SMARTpool, inhibiting Egr1 expression with either of the individual oligos 
significantly reduced c-Myc-induced apoptosis in p53-/- MycER MEFs as 
compared to control treated cells (Fig. 3-5).  Confirmation of this result with two 
different individual siRNA oligos and a smartpool decreases the likelihood  that 
the reduction of apoptosis is due to off-target effects.  
 
Egr1 is necessary specifically for c-Myc-induced p53-independent apoptosis 
 To compare the effects of Egr1 inhibition on c-Myc-induced apoptosis in 
MEFs  with  different  genetic  backgrounds,  we  treated  p53-/-, DKO, ARF-/-, and 
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Figure 3-3.   Egr1 and ARF are necessary for c-Myc induced p53-independent 
cell death. p53-/- MycER MEFs (+/-OHT) treated with siEgr1, siARF, siEgr1 and 
siARF, or control SMARTpool #1 for 24 hrs were assayed for apoptosis in low 
serum three days following OHT activation by counting living and dead cells with a 
hemacytometer.  The results are reported as the average number of dead cells 
multiplied by 100 divided by the number of total cells +/- standard deviation. 
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Figure 3-4.  Egr1 is necessary for c-Myc induced p53-independent 
apoptosis. Caspase-3 activity was determined in siEgr1 or siCtl treated p53-/- 
MycER MEFs +/- OHT for three days as described in the Materials and Methods.  
Results are reported as the average µmol pNA hydrolyzed per min per ml of cell 
lysate +/- standard deviation. 
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WT-MycER MEFs with Egr1 siRNA.  As previously shown, activation of c-MycER 
did not induce apoptosis in MEFs lacking p53 and ARF (Qi et al. 2004), and 
inhibition of Egr1 expression had no effect on the cells (Fig. 3-6).  However, 
activation of c-MycER in both ARF-/- and in wild type MycER MEFs did cause 
apoptosis (Fig. 3-6).  This confirms that c-Myc can induce apoptosis 
independently of ARF in cells with p53, which has been previously shown 
(Eischen et al. 1999).  Importantly, inhibition of Egr1 by siRNA had no effect on 
p53-dependent, ARF-independent c-Myc-induced apoptosis observed in ARF-/- 
MEFs (Fig. 3-6) or apoptosis caused by staurosporine treatment (Fig. 3-7), 
suggesting that reducing Egr1 levels does not cause a general defect in 
apoptosis, but rather Egr1 is specifically necessary for c-Myc-induced, p53-
independent apoptosis.  
 
Egr1 is sufficient for p53-independent apoptosis 
 Finally, to determine whether Egr1 is capable of inducing apoptosis 
without activated c-Myc or p53, we generated p53-/- MEFs expressing an Egr1-
ER fusion protein (Fig. 3-8, lower panel).  Upon four days of activation with OHT 
treatment, Egr1-ER efficiently induced apoptosis in low serum unlike OHT 
treatment in cells with vector alone (Fig. 3-8, upper panel).  Overall, these results 
suggest that Egr1 is necessary and sufficient for mediating p53-independent and 
ARF-dependent c-Myc-induced apoptosis.  
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Figure 3-5.  Treatment with single siRNA oligos targeting Egr1 is sufficient 
to reduce c-Myc-induced p53-independent apoptosis. The four siRNAs 
targeting Egr1 in the SMARTpool were individually (designated as siEgr1 c1, c2, 
etc.) used to knockdown Egr1 expression. (lower panel) The Western Blot analysis  
demonstrates that c1 and c3 most effectively reduced Egr1 levels compared to non-
targeting control pool #2 in p53-/- MycER MEFs.  (top panel) p53-/- MycER MEFs (+/-
OHT) treated with siEgr1 c1, siEgr1 c2, or control SMARTpool #2 for 24 hrs were 
assayed for apoptosis in low serum 3 days following OHT activation as described in 
the Materials and Methods.  The average percent dead, as calculated in Fig. 3-3, is 
reported +/- standard deviation. 
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Figure 3-6.  Egr1 is necessary for c-Myc-induced p53-independent 
apoptosis, but not p53-dependent apoptosis.  p53-/- MycER, DKO-MycER, 
ARF-/- MycER, and WT-MycER MEFs treated with either siEgr1 or siCtl were 
assayed for apoptosis and the results are calculated and reported as in Fig 3-3.  
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Egr1 is necessary for apoptosis induced by c-MycN6KR-ER 
 If the ARF interaction is switching c-Myc from driving canonical target 
gene activation to inducing Egr1 by inhibiting N-terminal ubiquitination, as 
suggested in the previous chapter, and if the induction of apoptosis is a result of 
the differential induction of target genes, as suggested in this chapter, then the 
activation of the N-terminal ubiquitination mutant, c-MycN6KR-ER, in DKO MEFs 
without ARF expression, should limit hyperproliferation and induce apoptosis as if 
ARF is present and interacting with c-Myc.  To test this idea, we examined the 
ability of c-MycN6KR-ER to induce hyperproliferation, transformation, and 
apoptosis compared to wild type c-MycER.  We first examined the ability of wild-
type c-Myc to induce hyperproliferation in DKO MEFs lacking both ARF and p53. 
Activated wild-type c-MycER induces hyperproliferation by approximately 2-fold 
(Zhang and Gregory, unpublished observations). In contrast, activation of c-
MycN6KR-ER resulted in a two-fold decrease in proliferation (Zhang and 
Gregory, unpublished observations).  Additionally, the ability of c-MycN6KR-ER 
to induce anchorage-independent growth in DKO MEFs is significantly reduced 
compared to wild-type c-MycER (Zhang and Gregory, unpublished observations).  
The inhibition of c-Myc-induced proliferation and transformation through inhibition 
of N-terminal ubiquitination is similar to the published effects of ARF on c-Myc (Qi 
et al. 2004).  To observe the effects of the loss of c-Myc N-terminal ubiquitination 
on apoptosis in a standard apoptotic assay, we placed DKO MEFs expressing 
either c-MycER or c-MycN6KR-ER in low serum and activated the ER-fused Myc 
proteins with OHT.   As we found previously, activated wild-type c-MycER did not 
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Figure 3-7.  Inhibition of Egr1 expression does not inhibit staurosporine-
induced apoptosis.  p53-/- MycER MEFs treated with siEgr1 or control SMARTpool 
for 24 hrs were treated with or without staurosporine.  Apoptosis was assayed 24 
hours later by counting living and dead cells with a hemacytometer.  Results were 
calculated and are reported as in Fig. 3-3.  
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Figure 3-8.  Activation of Egr1ER induces apoptosis in p53-/- MEFs.  (upper 
panel) p53-/- Egr1ER and p53-/- pBabe vector MEFs were assayed for apoptosis.  
Results are reported as the average percent dead +/- s.d. following four days of 
treatment (+/- OHT) in 1% serum media.  (lower panel) Western Blot shows Egr1ER 
expression following stable retroviral infection in p53-/- MEFs. 
 
 
 79	  
induce apoptosis in cells lacking ARF (Figure 3-9, upper panel) (Qi et al. 2004). 
In contrast, c-MycN6KR-ER efficiently induced rapid cell death (Figure 3-9, upper 
panel).  Apoptosis was confirmed by Western blot analysis of active caspase 3 
(data not shown).  Furthermore, we demonstrated that inhibition of Egr1 
expression by siRNA also significantly inhibited the ability of c-MycN6KR to 
induce apoptosis in DKO MEFs (Figure 3-9, lower panel), just as it prevented 
apoptosis by the activation of wild-type MycER in p53-/- MEFs.  These results 
suggest that the N-terminal ubiquitination mutant of c-Myc is inducing p53-
independent apoptosis through Egr1, just like wild-type c-Myc does in the 
presence of ARF.  
 
Discussion 
 The apoptotic potential of c-Myc acts as a built-in fail-safe mechanism that 
limits hyperproliferation and transformation caused by deregulated expression of 
itself.  One prevailing view is that c-Myc induces apoptosis through the indirect 
induction of ARF that ultimately leads to stabilization of p53 (Sherr 1998).  
However, c-Myc can also induce apoptosis though less-defined p53-independent 
mechanisms (Meyer et al. 2006).  In one such mechanism, ARF directly interacts 
with c-Myc leading to a reduction of hyperproliferation and transformation and the 
induction of apoptosis (Qi et al. 2004).  In this chapter, we explored how the c-
Myc/ARF   interaction   leads   to   p53-independent  apoptosis.   Specifically,  we  
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Figure 3-9. c-MycN6KR induces apoptosis in p53/ARF double knockout 
MEFs. A) One day after seeding at 1X105 cells/35mm dish in media containing 
10% BCS, MycER and MycN6KR-ER DKO MEFs were shifted into media 
containing 1% BCS and the cells were treated with 2 µM OHT as indicated and 
re-fed with media containing 2 µM OHT daily. B) MycN6KR-ER DKO MEFs were 
treated with either siGENOME Smart Pool targeting Egr1 or Smart Pool control.  
The next day the cells were split into triplicate plates in DMEM containing 2%CS 
with either OHT or ethanol.  The average percent dead +/- standard deviation 
was determined and calculated as described in the Materials and Methods. 
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demonstrated that the ARF-dependent noncanonical induction of Egr1 is essential 
for c-Myc to induce apoptosis independently of p53.  Thus, ARF binding 
essentially switches the inherent activity of c-Myc to an apoptotic protein through 
transcriptional regulation.  Several previously identified canonical c-Myc target 
genes can induce apoptosis, including ODC (Packham and Cleveland 1994) and 
MT-MC1 (Yin et al. 2002); however, it has not been shown conclusively that reduced 
expression of either of these or any other canonical direct target gene disrupts c-
Myc-induced apoptosis independently of p53.  Therefore, we demonstrate the first 
ARF-dependent c-Myc target gene that is necessary for p53-independent apoptosis.  
 As summarized in Fig. 3-10, our model is that under normal physiological low 
ARF conditions, c-Myc induces canonical target genes, such as cyclin D2, cdk4, 
nucleolin, eIF4E, and Egr2, which stimulate cell cycle progression and cell 
growth.  Under normal conditions p53 levels are also low due to Mdm2-mediated 
degradation of p53 protein.  Upon oncogenic activation, c-Myc causes both an 
increase in ARF expression and a relocalization of ARF from the nucleolus to the 
nucleoplasm, independently of p53 (Qi et al. 2004).   In a direct feedback 
mechanism, ARF binds with c-Myc to inhibit canonical c-Myc target gene 
induction and proliferation, while inducing noncanonical expression of Egr1 and 
Egr1-mediated apoptosis.  In cells with wild-type p53, elevated ARF also inhibits 
Mdm2 activity, leading to p53 protein stabilization and p53-induced apoptosis.  In 
cells  that  lack  functioning  ARF,  but  have  a wild-type p53, c-Myc induces p53-  
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Figure 3-10.  Model of c-Myc-ARF-Egr1 pathway.  c-Myc induces canonical target 
genes under normal physiological conditions when ARF is low, leading to 
proliferation (top panel).  p53 levels are also low under normal conditions due to 
Mdm2-mediated degradation of p53 protein.  Upon oncogenic activation of c-Myc, 
ARF directly interacts with c-Myc and inhibits canonical target gene expression 
necessary for proliferation.  ARF also switches c-Myc to an apoptotic protein that 
induces Egr1 through a noncanonical mechanism, which then mediates c-Myc-
induced apoptosis independently of p53 (lower panel).  In p53-dependent apoptosis, 
elevated ARF induced by oncogenic c-Myc also binds to and inhibits Mdm2 activity, 
leading to p53 stabilization and apoptosis.  c-Myc-induced apoptosis can also occur 
independently of ARF through alternate p53-dependent mechanisms.   
 
 
 
 
 
 
 83	  
 
 
 
 
 
 
 
 
 
 84	  
dependent apoptosis through less-defined mechanisms (Zindy et al. 1998; 
Pusapati et al. 2006). 
 Finally, in this chapter, we showed that the inhibition of c-Myc N-terminal 
ubiquitination can mimic or substitute for the necessity of ARF in c-Myc-mediated 
apoptosis and that the ubiquitination status of c-Myc controls the ability of c-Myc 
to induce apoptosis in fibroblasts.  Therefore, both the interaction of ARF with c-
Myc and the loss of N-terminal domain ubiquitination, switch c-Myc from a 
proliferative to an apoptotic protein and induces a novel apoptotic pathway 
through Egr1 expression.  
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CHAPTER IV 
 
CONCLUSIONS 
 
The Myc/ARF/Egr1 pathway as a fail-safe mechanism 
The c-myc proto-oncogene encodes an enigmatic transcription factor that 
paradoxically has essential roles in the regulation of both proliferation and apoptosis. 
Additionally, deregulated c-myc expression combined with a loss of tumor 
suppressors, manifested in many types of human cancers, causes 
hyperproliferation, transformation, and tumorigenesis.  Despite the extensive insight 
gained through meticulous examination of Myc over the past 30 years, questions 
remain about the molecular mechanisms governing the diverse and critical roles of 
c-Myc.  How does a single protein govern both survival and death?  Is there a signal 
that switches the function of c-Myc from driving proliferation to initiating apoptosis?  
How do cancerous cells overcome this signal?  Distinct threshold levels of c-Myc, 
which are regulated by various signaling pathways or deregulated in cancer, are 
correlated with different biological outcomes, such as transformation or apoptosis 
(Murphy et al. 2008).  But it is unclear if elevated c-Myc levels lead to merely an 
amplification of the same target genes induced by lower levels of c-Myc, or if an 
increase in c-Myc expression leads to the binding and activation of additional 
targets.  Considering that cell context also influences the biological outcomes 
initiated by elevated c-Myc, it is possible that additional cellular factors directly or 
indirectly modulate specific c-Myc target genes.  In this dissertation, it was shown 
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that a cofactor of c-Myc, the ARF tumor suppressor, switches the inherent function 
of c-Myc from a proliferative protein to an apoptotic protein through the 
transcriptional regulation of Egr1 (Boone et al. 2011).  Hopefully, through further 
understanding of this and other natural mechanisms that protect cells from 
uncontrolled c-Myc expression, specific therapies can be developed to prevent or 
treat c-Myc-driven human cancers. 
Apoptosis induced by oncogenic c-Myc occurs with or without p53 (Meyer 
et al. 2006).  In the ARF-MDM2-p53 pathway elevated or deregulated c-Myc 
levels indirectly induce ARF, which then stabilizes p53 through direct binding and 
inhibition of MDM2, the E3 ubiquitin ligase of p53 (Sherr 1998).  The increased 
levels of p53 then induce apoptosis through transactivation of direct pro-apoptotic 
target genes, such as Bax and PUMA (Zambetti et al. 1992).  c-Myc can also 
indirectly cause p53-dependent apoptosis without ARF by inducing a DNA 
damage response leading to activation of the ATM/ATR kinases and 
phosphorylation-mediated stabilization of p53 (Pusapati et al. 2006).  However, 
how c-Myc induces apoptosis independently of p53 has not been described.  We 
now demonstrate that ARF is necessary for the induction of a novel c-Myc target 
gene, Egr1, which is essential for c-Myc-driven p53-independent apoptosis 
(Boone et al. 2011).  Although, this Myc-ARF-Egr1 pathway is critical for the ability 
of c-Myc to induce apoptosis independently of p53, it is not necessary for p53-
dependent c-Myc-induced apoptosis, suggesting that it is a distinct and alternative 
fail-safe mechanism. 
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ARF:  an unusual cofactor 
In addition to ARF, there are many other cofactors that are necessary for or 
influence c-Myc transcriptional activity and biological functions.  Max, TRRAP, 
Mediator, and PTEFb are examples of cofactors that are essential for basic 
transcriptional activities such as DNA binding, recruiting general machinery for 
chromatin modification and remodeling, and activation of RNA polymerase II 
(Cowling and Cole 2006).  Other c-Myc cofactors, such as the ubiquitin E3 
ligases Skp2 (Kim et al. 2003; von der Lehr et al. 2003) and HectH9 (Adhikary et 
al. 2005), stimulate canonical transcription and cell cycle progression.  Another 
cofactor, nucleophosmin (NPM), also enhances canonical transcription and 
significantly stimulates c-Myc-induced hyperproliferation and transformation (Li et 
al. 2008).  In contrast, interaction of c-Myc with cofactor Bin1 inhibits c-Myc 
transactivation and induces caspase-independent apoptosis through an unknown 
mechanism (Sakamuro et al. 1996).  Other proteins also interact with c-Myc to 
influence apoptosis through different mechanisms.  For example, c-Myc appears 
to be a cofactor of the transcription factor Miz1, since Miz1 recruits c-Myc to Miz1 
target genes to inhibit transcription, leading to an induction of apoptosis and an 
inhibition of cell adhesion, perhaps through the repression of anti-apoptotic 
genes (Adhikary et al. 2005; Herkert et al.).  However, we now show that ARF is 
unlike any of these known cofactors in that it differentially regulates which c-Myc 
target genes are expressed.  Through this differential regulation of target genes, 
the interaction of ARF switches the inherent function of c-Myc from driving 
proliferation to initiating apoptosis.  
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ARF has a dual role in regulating c-Myc transcriptional activity.  ARF 
interacts directly with c-Myc and inhibits target genes, such as cdk4, tert, eIF4E, 
and Egr2, which possess canonical Myc E-box binding sites (CACGTG) (Qi et al. 
2004).  Interestingly, ARF is recruited to these canonical target genes with c-Myc to 
inhibit transcription, while also being recruited with c-Myc to the noncanonical target 
gene Egr1 to activate transcription (Boone et al. 2011).  While c-Myc can be 
recruited to the Egr1 promoter without ARF, ARF significantly increases recruitment 
of c-Myc to the promoter and is necessary for transcriptional induction of Egr1 by c-
Myc, which is necessary and sufficient to induce p53-independent apoptosis 
(Boone et al. 2011). In agreement with our results, Egr1 overexpression is 
sufficient to induce or enhance apoptosis in several different cell types, including 
MEFs (Das et al. 2001; Yu et al. 2007).  A pro-apoptotic, tumor suppressive role 
for Egr1, is also suggested by the findings that its expression is low or lost in 
many human tumors (Joslin et al. 2007; Liu et al. 2007).  Furthermore, although 
we have not established a role for Egr2 in c-Myc mediated biology, opposing 
roles of Egr1 and Egr2 have been found during adipocyte differentiation (Boyle et 
al. 2009) and T cell function (Collins et al. 2008), supporting our model that Egr1 
and Egr2 have different roles in mediating c-Myc function. 
 
Transcriptional regulation by ARF:  a p53-independent function 
In addition to transcriptional regulation of c-Myc, ARF regulates gene 
expression by directly interacting with and altering the location and/or the 
transactivaton/transrepression ability of multiple other transcription factors such 
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as E2F, Foxm1β, BCL6, p63, and interestingly, Egr1 (Datta et al. 2003; Calabro 
et al. 2004; Kalinichenko et al. 2004; Datta et al. 2005; Suzuki et al. 2005; Yu et 
al. 2009).  One study demonstrated that ARF directly inhibited E2F mediated 
transcription by directly binding and preventing the dimerization of E2F with DP1 
(Datta et al. 2003; Datta et al. 2005), suggesting that one possible mechanism of 
ARF regulation of transcription factors is through the competition with cofactors.  
Alternatively, the ARF interaction with Egr1 controls Egr1 transcriptional functions 
through sumoylation mediated by binding the SUMO-conjugating enzyme Ubc9 
(Yu et al. 2009).  In fact, ARF-mediated sumoylation of Egr1 is necessary for 
Egr1 to induce the tumor suppressor PTEN, suggesting that another possible 
mechanism of ARF regulation of transcription factors is through alterations of 
post-translational modifications (Yu et al. 2009).  These facts combined with our 
observations that the interaction of ARF with c-Myc reduces ubiquitination, and 
that the c-MycN6KR mutant mimics the Myc/ARF interaction in that it induces 
Egr1 and apoptosis independently of p53, suggests that the ARF interaction is 
differentially affecting c-Myc transcriptional and biological activities through a 
change in c-Myc post-translational modifications.  Because both sumoylation and 
ubiquitination occur on lysine residues, it is possible that the change in 
ubiquitination levels could be due to ARF-mediated sumoylation of the N-terminal 
lysines, thus leading to a blockage of ubiquitination.  In contrast, it could also be 
that the ARF interaction is preventing the binding of an E3 ubiquitin ligase of c-
Myc, thus inhibiting ubiquitination.  Or it could be a combination of both 
mechanisms.  Regardless, our results solidify that a p53-independent function of 
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ARF is transcriptional regulation. The first indication of p53-independent tumor 
suppressor functions of ARF came from knockout mice. Mice that are null for 
ARF, p53, and mdm2 develop a wider variety of tumors and at a frequency 
greater than those observed in mice lacking p53/mdm2 or p53 alone (Weber et 
al. 2000).  Further, reintroduction of ARF into ARF/mdm2/p53 triple null MEFs 
caused growth arrest of these cells and caused inhibition of proliferation and 
apoptosis in p53-deleted SAOS-2 osteosarcoma cells (Korgaonkar et al. 2002; 
Yarbrough et al. 2002).  However, despite years of research since those findings, 
describing the p53-independent functions of ARF has been largely controversial.   
	  
The cofactor switch model	  
Few direct c-Myc target genes like Egr1 have been identified that mediate 
a specific c-Myc function, giving rise to the idea that it takes multiple target genes 
to mediate any c-Myc function.  Interestingly, Egr1 is a transcription factor, like c-
Myc, that regulates the expression of a large number of target genes, some of 
which have been shown to be indirect targets of c-Myc (Krones-Herzig et al. 
2003; Krones-Herzig et al. 2005; Rogulski et al. 2005; Kubosaki et al. 2009).  In 
addition, the Egr1 binding site is the most commonly occurring cis-regulatory 
element found near c-Myc binding sites throughout the genome (Elkon et al. 
2004), suggesting that Egr1 and c-Myc may cooperatively or antagonistically 
regulate certain genes.  Furthermore, MT-MC1, another c-Myc target gene that 
can substitute for c-Myc in sensitizing cells to apoptosis, is a DNA binding protein 
that alters the expression of 47 different genes, all of which have both c-Myc and 
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Egr1 binding sites in their promoters (Rogulski et al. 2005).  In fact, there is 
experimental evidence that c-Myc and Egr1 bind simultaneously to 7 different 
promoters (Elkon et al. 2004).  Therefore, we speculate the importance of Egr1 
as a target gene, is due to sequential and/or simultaneous, cooperative and/or 
antagonistic, regulation of other targets—in other words, c-Myc initiates a wave 
of transcription through Egr1.  This could be a possible explanation for the large 
number of generally non-overlapping potential c-Myc target genes that have been 
identified by numerous studies using different cell types and conditions.  Perhaps c-
Myc, in different cell contexts depending on the interaction of specific cofactors 
like ARF, directly induces a variety of transcription factors, in this case Egr1, 
which in turn can sequentially or cooperatively regulate a large number of genes.  
In this general “Cofactor Switch“ model depicted in Figure 4-1, a cofactor like 
ARF could control a large number of genes for specific c-Myc functions (Figure 4-
1).   
It is understood, however, that this simple model becomes very complex 
when you consider that there are many cofactors of c-Myc that are 
simultaneously expressed and competing for binding.  It is unknown how the 
relative abundance of these different cofactors and/or their differential binding 
affinities controls c-Myc function.  Additionally, under certain conditions, there 
may be a heterogeneous mixture of c-Myc complexes that directly compete 
against one another.  For example, under low ARF conditions, when there is a 
stoichiometric excess of c-Myc, there could be both c-Myc that is bound to ARF 
and  c-Myc  that  is  not.  In  this  scenario,  some  molecules  of  c-Myc  could be 
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Figure 4-1.  Cofactor Switch Model.  In addition to cofactors being able to 
inhibit or enhance the c-Myc transcriptional response, ARF, and we propose that 
other cofactors, can also differentially switch the response, whereby shutting off 
targets induced before binding, such as Target1, Target2…, while being 
necessary to induce new targets, such as Targetα, Targetβ… Furthermore, if the 
new targets are transcription factors or other proteins important for gene 
regulation, like Targetα then this could elicit a wave of transcription —induction of 
new targets such as Targetα1, Targetα2…— that ultimately leads to specific 
biological functions. 
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inducing the pro-apoptotic target Egr1, while others could be inducing 
proliferative targets like cyclinD2.  How the cell would resolve this conflict is 
unknown.  Another of many layers of complexity comes from the fact that not a 
single c-Myc target gene has been found that is only regulated by c-Myc.  So, 
when considering the ultimate transcriptional regulation of any target and the 
consequential biological outcome(s), we must take into consideration that other 
signaling pathways indirectly influence the ability of c-Myc to regulate its targets.   
 
Future Directions 
Though we have now established the Myc/ARF/Egr1 apoptotic pathway, 
many questions remain.  How does ARF differentially regulate c-Myc targets?  
Does it compete with other cofactors?  Does it recruit new cofactors to c-Myc or 
the DNA of target genes?  Does it affect important posttranslational modifications 
of c-Myc?  Though the data that ARF inhibits ubiquitination and that the 
MycN6KR mutant mimics ARF’s effects on c-Myc’s transcription and biological 
functions does suggest that ARF is influencing Myc transcription through the 
alteration of ubiquitination, we still do not know by what mechanism.  We are 
currently investigating if ARF is competing for Myc binding with known ubiquitin 
ligases.  Additionally, it is difficult to envision a clear mechanism for how the 
Myc/ARF complex binds and inhibits certain targets, but is necessary for the 
induction of another target, Egr1.  It could be that the regulation is promoter 
specific.  Because of this, it will be important to identify the exact noncanonical 
site through which c-Myc and ARF regulate the Egr1 promoter, and to determine 
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if the regulation of this noncanonical site is crucial for other c-Myc targets.  Once 
promoter bashing is complete and the site or sites are identified, it would be 
interesting to combine a siRNA screen with luciferase assays to determine if 
other factors are important for the c-Myc/ARF induction of Egr1.  Furthermore, 
we still do not understand the mechanism of how induction of Egr1 stimulates 
apoptosis.  Others have shown that Egr1 has many downstream targets that are 
important apoptotic genes, like PTEN and Bax (Virolle et al. 2001; Krones-Herzig 
et al. 2003; Baron et al. 2006; Yu et al. 2007).  However, it will be essential to 
identify what is downstream of Egr1 that induces c-Myc-driven p53-independent 
apoptosis.  While a ‘gene at a time’ approach could identify an important 
downstream target, a combination of global gene expression and a large-scale 
apoptotic screen after treatment with a siRNA library, would be ideal to fully 
understand the pathway.  Finally, it would be interesting to understand how c-
Myc and Egr1 regulate genes together.  As stated above, the two transcription 
factors share many targets, and it has been demonstrated through ChIP 
analyses that for at least some targets, they bind to the same promoter at the 
same time (Elkon et al. 2004).  However, it is not known if they regulate genes 
sequentially and/or simultaneously.  Nor is it known if they act cooperatively 
and/or antagonistically on target gene promoters.  Understanding how Myc 
functions and interacts with other transcription factors on promoters, as well as, 
waves of transcription elicited by c-Myc could be key to comprehending the 
broad reach of c-Myc’s biological functions.  
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The Myc-ARF-Egr1 pathway may play an important role in restraining c-
Myc-induced tumorigenesis.  Our finding that Egr1 is essential for p53-
independent c-Myc-induced apoptosis and the observations that Egr1 expression 
is low or lost in many human tumors suggest that the Myc-ARF-Egr1 pathway 
plays a key role in c-Myc-induced apoptosis and indicates that this pathway is 
disabled in tumors even with an intact ARF gene.  Successful chemotherapy 
strategies depend on induction of cell death in the targeted tumor.  Further 
understanding the mechanism controlling this pathway could be critical for future 
cancer therapeutic approaches by unleashing the inherent apoptotic function of 
c-Myc.  
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